LLY
Eli Lilly
$1.35Tn
1,433.04
+1.34%
+48.25%
Eli Lilly discovers, develops, manufactures, and markets branded prescription drugs across therapeutic areas such as cardiometabolic health, oncology, immunology, and neuroscience. Its revenue is primarily generated from the sale of branded pharmaceutical products like insulin analogs and GLP-1 receptor agonists.
JNJ
Johnson & Johnson
$675.90Bn
280.77
-0.46%
+49.02%
The company's Innovative Medicine segment generates significant revenue from branded prescription pharmaceuticals such as STELARA, TREMFYA, and XARELTO. These products are sold to retailers, wholesalers, and hospitals for the treatment of oncology, immunology, and cardiovascular diseases.
ABBV
AbbVie
$519.45Bn
293.87
+0.33%
+34.37%
AbbVie is a diversified pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as Vraylar, Ubrelvy, Qulipta, and Mavyret.
MRK
Merck
$364.95Bn
148.04
-0.47%
+70.65%
Merck's primary revenue driver is the sale of branded prescription pharmaceuticals and vaccines for human health, with 2025 pharmaceutical sales totaling $58,142 million. Key branded products cited include Keytruda, Gardasil, and Januvia.
NVS
Novartis Ag
$311.58Bn
163.29
-0.26%
+28.37%
Novartis is an innovative medicines company that researches, develops, manufactures, and markets branded prescription pharmaceuticals across therapeutic areas such as cardiovascular, renal, metabolic diseases, immunology, neuroscience, and oncology. Its primary revenue is generated from the sale of these pharmaceutical products to wholesalers, health systems, and government agencies.
AZN
Astrazeneca
$289.34Bn
186.67
-1.42%
+6.69%
AstraZeneca is a global biopharmaceutical company that discovers, develops, and markets branded prescription medicines. Its revenue is primarily driven by the sale of branded pharmaceutical products such as Tagrisso, Farxiga, and Symbicort across various therapeutic areas.
AMGN
Amgen
$251.64Bn
465.23
+0.00%
+43.74%
Amgen is explicitly described as a leading independent biotechnology company that researches, develops, and commercializes therapies derived from biological science. Its revenue is generated from the sale of therapeutic medicines such as Enbrel and Repatha, which are biologic products.
GILD
Gilead Sciences
$212.05Bn
170.87
+0.92%
+44.62%
Gilead is a biopharmaceutical company that develops therapies derived from biological science, including monoclonal antibodies and CAR T cell therapies like Yescarta and Tecartus. Its revenue is driven by the sale of these biologic products and royalties from collaborations.
ABT
2nd
Abbott Laboratories
$191.31Bn
110.46
-0.06%
-12.26%
The Established Pharmaceutical Products segment markets branded generic pharmaceuticals and biosimilars, such as Creon and Synthroid, primarily in emerging markets.
PFE
Pfizer
$167.35Bn
29.36
+0.41%
+20.38%
Pfizer is a global biopharmaceutical company that discovers, develops, and markets a vast portfolio of branded prescription drugs and vaccines, including Eliquis, Prevnar, and Paxlovid. Its primary revenue is generated from the sale of these branded pharmaceutical products to hospitals, patients, and healthcare providers.
VRTX
Vertex Pharmaceuticals
$138.90Bn
547.89
-0.54%
+30.08%
Vertex is described as a global biotechnology company that develops therapies derived from biological science, including proteins and biologics. Its revenue is derived from the sale of biologic products, collaboration milestone payments, and royalties.
BMY
Bristol Myers Squibb
$128.39Bn
62.81
+1.06%
+32.90%
Bristol Myers Squibb is a large pharmaceutical firm that discovers, develops, and markets a wide portfolio of branded prescription medicines such as Eliquis, Sprycel, and Abraxane. Its revenue is primarily generated from the sale of these innovative branded pharmaceuticals across multiple therapeutic areas.
GSK
Gsk
$110.56Bn
51.24
-0.49%
+8.19%
GSK is a global biopharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded products such as Dovato, Cabenuva, and Nucala.
MRNA
Moderna
$101.34Bn
250.83
-6.71%
+913.05%
Moderna is a biotechnology company that researches and commercializes therapies derived from biological science, specifically messenger RNA (mRNA). Its revenue is generated from the sale of biologic products like Spikevax and mRESVIA, as well as collaboration and licensing revenue.
REGN
Regeneron Pharmaceuticals
$93.16Bn
916.06
-0.49%
+39.91%
Regeneron is a biotechnology company that develops and commercializes therapies derived from biological science, specifically using its VelociSuite and Trap technology to produce fully human antibodies and bispecific molecules. Its revenue is driven by the sale of biologic products such as EYLEA, Dupixent, and Libtayo, as well as collaboration and royalty payments.
COR
2nd
Cencora
$66.55Bn
348.73
+0.85%
-4.37%
The company operates the MWI Animal Health business, which generates revenue through the distribution of animal health products and veterinary supplies to animal health providers.
ARGX
Argenx Se
$60.12Bn
971.55
+0.96%
+11.69%
Argenx is a biopharmaceutical company that develops and commercializes antibody-based therapeutics, such as VYVGART, which is an FcRn inhibitor. Its revenue is derived from the sale of these biologic products and from milestone payments and royalties from collaborations with partners like Zai Lab and AbbVie.
SNY
Sanofi
$58.81Bn
48.23
+0.23%
-4.80%
Sanofi is a global pharmaceutical company that discovers, develops, and markets branded prescription drugs across multiple therapeutic areas. Its revenue is primarily derived from the sale of branded medicines such as Dupixent for immunology and Sarclisa for oncology.
IDXX
Idexx Laboratories
$54.89Bn
696.64
-1.42%
-1.82%
The company's primary business is focused on the animal health market, providing diagnostic products and services for companion animals, livestock, poultry, and dairy. Key products include the IDEXX VetLab suite, Catalyst One Chemistry analyzer, and tests for Bovine Viral Diarrhea Virus.
TEVA
Teva Pharmaceutical Industries
$49.47Bn
42.40
-1.37%
+74.77%
Teva is described as a biopharmaceutical company with a strong generics business, ranking among the top three global suppliers of generic prescription drugs. Its revenue is primarily driven by a broad generic portfolio including oral solids, injectables, and inhalants marketed to wholesalers and pharmacies.
ONC
BeOne Medicines
$48.38Bn
424.00
+1.60%
+28.80%
BeOne Medicines discovers, develops, and markets branded prescription drugs for oncology, specifically hematology and solid tumors. Its primary revenue is derived from the sales of branded medicines such as BRUKINSA and TEVIMBRA.
RVMD
Revolution Medicines
$41.75Bn
193.06
-3.54%
+207.76%
Revolution Medicines is a clinical-stage company developing small-molecule RAS(ON) inhibitors for cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. Its core business is the discovery and development of branded prescription pharmaceuticals based on its proprietary tri complex technology platform.
GEHC
2nd
GE HealthCare Technologies
$37.82Bn
83.65
-0.45%
+13.84%
The Pharmaceutical Diagnostics segment develops and sells branded prescription pharmaceuticals, specifically contrast media and radiopharmaceutical imaging agents used in radiology and nuclear medicine.
BIIB
Biogen
$37.44Bn
253.25
-0.64%
+62.07%
Biogen is a biopharmaceutical company that researches and commercializes therapies derived from biological science, such as monoclonal antibodies and recombinant proteins. Its revenue is driven by biologic products like SPINRAZA for spinal muscular atrophy and LEQEMBI for Alzheimer's disease.
ALC
2nd
Alcon
$36.19Bn
74.25
-1.25%
-0.19%
Alcon develops and markets branded prescription pharmaceuticals for ocular health, including Rocklatan and Rhopressa for the treatment of glaucoma.
ZTS
Zoetis
$33.60Bn
82.45
+0.33%
-31.17%
Zoetis is a global leader in animal health, developing and selling medicines, vaccines, and parasiticides for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep). Its revenue is primarily generated from the sale of these animal-health products to veterinarians, pet owners, and livestock producers.
ROIV
Roivant Sciences
$29.81Bn
41.19
+1.28%
+94.57%
Roivant is a biopharmaceutical company that develops therapies derived from biological science, specifically monoclonal antibodies like IMVT 1402 and batoclimab. Its revenue model is based on biologic product development, collaboration milestones, and royalties from partners such as HanAll and Bayer.
INSM
Insmed
$26.21Bn
119.49
+2.92%
-37.74%
Insmed is a biopharmaceutical company that develops therapies derived from biological science, including the monoclonal antibody INS1148 and the Pulmovance liposomal platform used for ARIKAYCE. Its revenue is derived from the sale of these biologic-based products and potential milestone payments.
UTHR
United Therapeutics
$24.95Bn
588.61
+1.02%
+29.67%
The company's primary revenue is derived from the sale of branded prescription pharmaceuticals for pulmonary hypertension and oncology, specifically Tyvaso DPI, Remodulin, Orenitram, and Unituxin.
VTRS
Viatris
$23.90Bn
20.85
+1.76%
+105.01%
Viatris is described as one of the largest providers of generic medicines globally, generating significant revenue from simple and complex generics, biosimilars, and specialty generics. The profile explicitly highlights its position as a major player in the generic drug market competing with Teva and Sandoz.
BNTX
BioNTech SE
$22.05Bn
87.21
-0.34%
-17.00%
BioNTech is a biotechnology company that researches and commercializes therapies derived from biological science, specifically leveraging messenger RNA (mRNA) technology and protein-based therapeutics. Its revenue is derived from the sale of the mRNA-based COVID-19 vaccine Comirnaty and significant collaboration and milestone payments from partners like Pfizer and Bristol Myers Squibb.
ZBH
2nd
Zimmer Biomet Holdings
$20.31Bn
107.30
-0.94%
+20.93%
The company's product portfolio explicitly includes biologics, which are therapies derived from biological science used in musculoskeletal health.
ALNY
Alnylam Pharmaceuticals
$20.30Bn
151.64
-3.17%
-65.67%
Alnylam is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically RNAi therapeutics consisting of small interfering RNA (siRNA). Its revenue is generated from the sale of biologic products such as AMVUTTRA, ONPATTRO, and GIVLAARI, as well as collaboration payments and royalties from partners like Novartis and Sanofi.
EXEL
Exelixis
$17.27Bn
70.58
-1.62%
+70.44%
Exelixis focuses on the discovery, development, and commercialization of branded prescription oncology medicines, specifically small molecule tyrosine kinase inhibitors. Its primary revenue is generated from the net product sales of branded drugs such as CABOMETYX and COMETRIQ.
NBIX
Neurocrine Biosciences
$17.13Bn
169.14
+0.17%
+12.74%
Neurocrine Biosciences develops and markets branded prescription drugs, with the vast majority of its revenue coming from the sale of INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia. These are branded small-molecule pharmaceuticals sold through specialty pharmacies and wholesale distributors.
ASND
Ascendis Pharma A
$15.90Bn
256.59
-1.25%
+30.91%
Ascendis Pharma is a biopharmaceutical company that uses its proprietary TransCon technology platform to develop therapies derived from biological science, such as SKYTROFA for growth hormone deficiency. Its revenue is generated from the sale of these biologic products and through collaboration milestone payments and royalties.
BBIO
BridgeBio Pharma
$15.42Bn
78.67
+0.95%
+25.25%
BridgeBio is a biopharmaceutical company that develops therapies derived from biological science to treat genetic diseases, such as acoramidis for ATTR-CM and infigratinib for achondroplasia. Its revenue model includes net product sales of Attruby, as well as milestone payments and royalties from collaborations with Bayer and Alexion.
KNSA
Kiniksa Pharmaceuticals International
$14.92Bn
95.02
-3.79%
+140.56%
Kiniksa is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies and cytokine traps like ARCALYST. Its revenue is derived from the sale of these biologic products, as well as milestone payments and royalties from licensing partnerships.
SMMT
Summit Therapeutics
$14.26Bn
17.83
-0.06%
-2.57%
Summit Therapeutics is a clinical-stage biopharmaceutical company developing ivonescimab, which is described as a bispecific antibody. Its revenue model is based on licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
GKOS
2nd
Glaukos
$13.97Bn
236.11
-1.23%
+167.24%
The company develops and commercializes branded pharmaceutical products, such as the iDose TR intracameral pharmaceutical implant and iLink therapies for corneal crosslinking. These branded prescription therapies represent a material portion of the company's revenue and product pipeline.
BAX
2nd
Baxter International
$13.66Bn
26.41
+0.00%
+48.79%
Baxter has a dedicated Pharmaceuticals segment that generates revenue from the sale of specialty injectable pharmaceuticals and inhaled anesthetics, which fall under specialty pharmaceuticals.
ELAN
Elanco Animal Health
$13.38Bn
26.78
-0.22%
+20.25%
Elanco develops, manufactures, and markets a diverse portfolio of animal health products, including parasiticides, vaccines, and pain therapeutics for both companion animals and livestock. Its revenue is derived from the sale of these veterinary pharmaceuticals and nutritional products to farmers, pet owners, and veterinarians.
MDGL
Madrigal Pharmaceuticals
$12.65Bn
432.60
-0.04%
-12.76%
Madrigal Pharmaceuticals is a biopharmaceutical company that developed Rezdiffra (resmetirom), a thyroid hormone receptor beta agonist, and maintains a pipeline of biologics including GLP-1 receptor agonists and siRNA programs. Its revenue is derived from the sale of these biology-based therapies for the treatment of MASH.
RDY
Dr Reddys Laboratories
$12.40Bn
14.86
-1.26%
+9.91%
The company's Global Generics segment contributes the majority of its income through the manufacturing and marketing of generic equivalents and biosimilar alternatives to reference drugs. It is explicitly described as one of the world's leading generic pharmaceutical companies.
HALO
Halozyme Therapeutics
$11.73Bn
102.98
+0.06%
+51.42%
Halozyme is a biopharmaceutical company that develops therapies and delivery platforms derived from biological science, specifically using recombinant human hyaluronidase (rHuPH20). Its revenue model is based on biologic product sales, licensing fees, milestone payments, and royalties from partners like Roche and Pfizer.
KYMR
Kymera Therapeutics
$11.66Bn
136.64
-1.60%
+123.05%
Kymera Therapeutics develops oral small molecule medicines, such as those targeting STAT6, IRF5, IRAK4, and CDK2, which are branded prescription pharmaceuticals. The company's core business is the discovery and development of these small-molecule drugs to treat immune inflammatory diseases and oncology.
BWXT
2nd
BWX Technologies
$11.61Bn
126.74
-0.90%
-36.24%
The company produces and sells radiopharmaceuticals and medical radioisotopes to hospitals and pharmaceutical firms for diagnostic and therapeutic applications.
BMRN
Biomarin Pharmaceutical
$11.06Bn
57.13
-0.09%
+8.47%
BioMarin is a biotechnology company that develops and commercializes therapies derived from biological science, specifically enzyme replacement therapies like VIMIZIM and NAGLAZYME for lysosomal storage disorders. Its revenue is driven by the sale of these biologic products and its focus on genetic medicine.
GMED
2nd
Globus Medical
$9.97Bn
75.23
-1.52%
-12.89%
The company sells biologics, including allografts and synthetic bone graft substitutes, which are biological therapies used to promote fusion in musculoskeletal procedures.
PCVX
Vaxcyte
$9.91Bn
66.36
-1.73%
+54.61%
Vaxcyte is a clinical-stage biotechnology company developing vaccines using its XpressCF cell-free protein synthesis platform to produce complex antigens. Its revenue model currently consists of research grants, collaboration funding, and potential milestone payments and royalties, which is characteristic of H-02.
TGTX
Tg Therapeutics
$9.71Bn
64.26
+1.39%
+112.08%
TG Therapeutics is a biotechnology company that commercializes BRIUMVI, an anti-CD20 monoclonal antibody, and develops other biologics. Its revenue is derived from the sale of this biologic product and milestone payments from collaborations.
PRAX
Praxis Precision Medicines
$9.44Bn
337.59
+1.39%
+101.08%
Praxis is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically antisense oligonucleotides (ASOs) via its Solidus platform. Its revenue model relies on collaboration, milestone payments, and royalties, which is characteristic of biotechnology developers.
SYRE
Spyre Therapeutics
$9.40Bn
104.48
-4.15%
+371.05%
Spyre Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies targeting α4β7, TL1A, and IL23. Its revenue model currently relies on collaboration and licensing arrangements, such as those with Paragon, which include milestone payments and royalties.
CHWY
2nd
Chewy
$9.17Bn
22.85
-0.91%
-32.42%
The company operates Chewy Pharmacy, which dispenses veterinarian-prescribed medications and compounded formulations, and provides in-person veterinary services through its Chewy Vet Care clinic network.
KRYS
Krystal Biotech
$9.08Bn
306.50
+1.14%
+53.61%
Krystal Biotech focuses on the discovery and commercialization of genetic medicines using a patented HSV1-based gene therapy platform. Its lead product, VYJUVEK, is a corrective gene therapy for dystrophic epidermolysis bullosa, and its pipeline includes inhaled and ophthalmic gene therapies.
PTGX
Protagonist Therapeutics
$8.89Bn
136.26
+0.26%
+63.71%
Protagonist Therapeutics is a biotechnology company that researches and develops peptide-based therapeutics, including oral and injectable peptides for inflammatory, immunologic, and metabolic diseases. Its revenue model consists of collaboration agreements, upfront payments, and milestone payments from partners like Janssen Biotech and Takeda Pharmaceuticals.
CORT
Corcept Therapeutics
$8.03Bn
73.35
-2.24%
-2.83%
Corcept Therapeutics discovers, develops, and markets branded prescription drugs, specifically its lead product Korlym for the treatment of hypercortisolism. Its revenue is generated from the sale of these branded pharmaceuticals to physicians and healthcare providers.
RYTM
Rhythm Pharmaceuticals
$7.90Bn
113.95
+0.01%
+16.72%
Rhythm Pharmaceuticals is a biopharmaceutical company that develops therapies derived from biological science, specifically melanocortin-4 receptor agonists like setmelanotide (IMCIVREE). Its revenue is generated from the sale of these biologic products and through collaboration, milestone, and royalty payments from partners like Ipsen and LG Chem.
CYTK
Cytokinetics
$7.83Bn
56.18
+1.89%
-9.68%
Cytokinetics develops and markets branded prescription drugs, specifically the oral small molecule inhibitor MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy. Its revenue is generated from the sales of these branded pharmaceuticals and associated licensing milestones.
ALKS
Alkermes
$7.81Bn
46.47
+0.76%
+42.33%
Alkermes develops and markets branded prescription drugs for neuroscience disorders, including ARISTADA, LYBALVI, VIVITROL, and LUMRYZ. Its primary revenue is generated through the direct sales of these proprietary branded pharmaceuticals.
BLCO
2nd
Bausch & Lomb
$7.64Bn
21.38
+1.91%
+33.88%
The company develops and markets branded prescription eye medications for conditions like glaucoma and dry eye, specifically citing products such as MIEBO, XIIDRA, and Vyzulta.
AMRX
Amneal Pharmaceuticals
$7.45Bn
21.38
+0.47%
+86.24%
The company's primary revenue driver is its Affordable Medicines segment, which focuses on generic pharmaceuticals, injectables, and biosimilars, including first-to-file and first-to-market opportunities.
ORKA
Oruka Therapeutics
$7.43Bn
109.50
+4.72%
+291.63%
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, such as ORKA 001 and ORKA 002, which are biologics. Its revenue model is based on the future commercialization of these biological products and potential collaboration or licensing payments.
AXSM
Axsome Therapeutics
$7.41Bn
140.97
+5.23%
+2.30%
Axsome is a fully integrated biopharmaceutical company that manufactures and markets branded prescription drugs, including AUVELITY for major depressive disorder, SUNOSI for excessive daytime sleepiness, and SYMBRAVO for migraine. Its core revenue stream comes from the sale of these branded pharmaceutical products in the United States.
IMVT
Immunovant
$7.38Bn
35.71
+1.59%
+52.80%
Immunovant is a clinical-stage biotechnology company developing therapies derived from biological science, specifically fully human monoclonal antibodies (IMVT-1402 and batoclimab). Its core business is the research and development of these biologics to treat autoimmune diseases.
IBRX
ImmunityBio
$7.17Bn
6.74
-5.20%
+212.04%
ImmunityBio is a biotechnology company that develops and commercializes therapies derived from biological science, specifically its lead biologic product ANKTIVA, an IL-15 receptor superagonist. The company generates revenue from the commercial sale of this biologic product for the treatment of BCG-unresponsive NMIBC CIS.
ABVX
Abivax
$7.07Bn
90.00
+3.45%
-15.19%
Abivax is a clinical-stage biotechnology company focused on discovering and developing therapeutics for chronic inflammatory diseases, specifically ulcerative colitis and Crohn's disease. Its revenue currently comes from research collaborations, licensing agreements, and grant funding, which is characteristic of the H-02 biotechnology classification.
ARWR
Arrowhead Pharmaceuticals
$6.92Bn
49.00
-0.49%
+22.96%
Arrowhead Pharmaceuticals researches and commercializes therapies derived from biological science, specifically using RNA interference (RNAi) and siRNA triggers to silence genes. Its revenue is generated from the sale of its biologic product REDEMPLO and through collaboration payments and royalties from partners like Amgen and Takeda.
KOD
Kodiak Sciences
$6.79Bn
108.06
+0.90%
+484.42%
Kodiak Sciences develops therapies derived from biological science, specifically using an Antibody Biopolymer Conjugate (ABC) platform to create monoclonal antibodies and bispecific proteins like tarcocimab tedromer (Zenkuda) and KSI-501. The company is a clinical-stage developer focusing on biology-based drug discovery for retinal diseases.
CGON
CG Oncology
$6.49Bn
72.64
-2.81%
+80.61%
CG Oncology is a clinical-stage biopharmaceutical company developing cretostimogene grenadenorepvec, an oncolytic immunotherapy derived from biological science. Its current revenue is generated through collaboration and milestone payments from partners like Kissei Pharmaceutical and Lepu Biotech.
SRRK
Scholar Rock Holding
$6.35Bn
48.00
-6.89%
+63.43%
Scholar Rock is a biopharmaceutical company that researches and develops therapies derived from biological science, specifically monoclonal antibodies like apitegromab and SRK 439. Its current revenue is derived from collaboration and milestone payments from partners such as Gilead, which is characteristic of clinical-stage biotechnology developers.
FMS
2nd
Fresenius Medical Care AG
$6.35Bn
22.74
-0.92%
-4.05%
The company develops and markets renal pharmaceuticals, specifically mentioning erythropoietin stimulating agents, iron sucrose, and phosphate binders.
LGND
Ligand Pharmaceuticals
$6.28Bn
314.16
+0.00%
+50.11%
Ligand is a biopharmaceutical company that develops and licenses biological platform technologies like Captisol and NITRICIL. Its revenue is primarily derived from royalties on biologic products such as Kyprolis and Qarziba, as well as milestone payments from biotechnology development programs.
BLTE
Belite Bio
$6.16Bn
156.52
-0.74%
+33.39%
Belite Bio is a clinical-stage company developing branded prescription drugs, specifically oral small molecules like tinlarebant (LBS 008) and LBS 009. These candidates target therapeutic areas such as Stargardt disease, geographic atrophy, and metabolic disorders like type 2 diabetes.
MIRM
Mirum Pharmaceuticals
$6.16Bn
94.42
+1.33%
+35.45%
Mirum Pharmaceuticals is a biopharmaceutical company that researches and commercializes therapies for rare diseases, such as Livmarli and Cholbam. Its revenue is derived from the sale of these biologic-based or specialized medicines, as well as milestone payments and royalties from collaborative agreements.
GRFS
Grifols
$5.96Bn
8.76
+0.81%
+1.86%
Grifols is a global producer of plasma derivatives, manufacturing biologic therapies such as immunoglobulins, albumin, and clotting factors (Factor VIII and IX). These are recombinant or plasma-derived proteins, which falls squarely under the biotechnology classification for therapies derived from biological science.
COGT
Cogent Biosciences
$5.50Bn
31.64
-5.66%
-2.53%
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies derived from biological science, such as the tyrosine kinase inhibitor bezuclastinib. Its revenue model currently relies on licensing agreements, milestone payments, and potential future royalties from its lead assets.
PTCT
Ptc Therapeutics
$5.36Bn
64.14
-1.37%
-11.51%
PTC Therapeutics is a biopharmaceutical company that develops and commercializes therapies derived from biological science for rare diseases. Its revenue is generated from the sale of biologic-based products such as Evrysdi for spinal muscular atrophy and Upstaza for aromatic L-amino decarboxylase deficiency.
EWTX
Edgewise Therapeutics
$5.09Bn
46.53
-4.53%
+154.54%
Edgewise Therapeutics focuses on discovering and developing small molecule therapies, such as sevasemten and EDG-7500, for muscle diseases. Because its pipeline consists of small-molecule drug candidates rather than biologics, it fits the Pharmaceuticals classification.
DNTH
Dianthus Therapeutics
$5.00Bn
88.81
-1.36%
+142.58%
Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like claseprubart and fusion proteins like DNTH212. Its revenue model consists of upfront payments, milestone payments, and royalties from collaboration agreements with partners such as Tenacia Biotechnology and Nanjing Leads Biolabs.
TVTX
Travere Therapeutics
$4.97Bn
51.99
+0.70%
+51.22%
Travere Therapeutics develops and markets branded prescription drugs for rare kidney and metabolic diseases, such as FILSPARI (sparsentan) for IgAN and Thiola for cystinuria. Its revenue is primarily generated from the sales of these branded pharmaceutical products.
ERAS
Erasca
$4.84Bn
15.48
-0.83%
+575.98%
Erasca is a clinical-stage biotechnology company developing therapies derived from biological science, specifically mentioning a biparatopic antibody candidate (ERAS 12) and a modality agnostic strategy including large molecule antibodies. Its revenue model currently relies on licensing agreements, milestone payments, and collaborations typical of biotech developers.
DFTX
Definium Therapeutics
$4.74Bn
34.64
-1.81%
+194.81%
Definium Therapeutics is developing branded prescription drugs for brain health disorders, specifically DT120 (lysergide d tartrate) and DT402 (R enantiomer of MDMA). These are small-molecule pharmaceutical compounds targeting generalized anxiety disorder, major depressive disorder, and autism spectrum disorder.
IONS
Ionis Pharmaceuticals
$4.69Bn
28.19
-9.06%
-59.46%
Ionis is a biotechnology company that develops RNA-targeted medicines using proprietary antisense technology to modify gene expression. Its revenue is derived from the sale of biologic-based products like SPINRAZA and QALSODY, as well as royalties and milestone payments from collaborations.
GPCR
Structure Therapeutics
$4.65Bn
21.73
+1.49%
-35.90%
Structure Therapeutics is a biopharmaceutical company focused on discovering and developing oral small molecule therapeutics, such as aleniglipron (a GLP1R agonist) and amylin receptor agonists. Because its pipeline consists of small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification.
LQDA
Liquidia
$4.60Bn
51.40
+7.37%
+88.55%
Liquidia develops and markets branded prescription drugs for respiratory and vascular conditions, specifically its lead commercial product YUTREPIA. Revenue is primarily derived from the sale of this branded pharmaceutical to patients and healthcare providers.
HIMS
2nd
Hims & Hers Health
$4.48Bn
19.15
-16.12%
-53.35%
The company sells and fulfills generic, brand name, and compounded medications through its own pharmacies and partner pharmacies.
RLAY
Relay Therapeutics
$4.38Bn
19.94
-1.82%
+223.18%
Relay Therapeutics is a clinical-stage biotechnology company that uses its Dynamo platform to develop small molecule therapies for cancer and genetic diseases. Its revenue is currently derived from collaboration and milestone payments from partners like Genentech and Pfizer, which is characteristic of the H-02 classification.
CRSP
CRISPR Therapeutics AG
$4.37Bn
45.15
-9.77%
-17.28%
CRISPR Therapeutics focuses on developing therapies that modify genes and cells using CRISPR/Cas9 technology, such as CASGEVY for sickle cell disease. Its core business revolves around gene editing platforms, including in vivo gene editing and CAR T cell therapies.
TNGX
Tango Therapeutics
$4.12Bn
24.30
+6.86%
+206.43%
Tango Therapeutics is a biotechnology company that researches and develops therapies derived from biological science, specifically using synthetic lethality to target cancer cells. Its revenue is currently derived from collaboration and licensing agreements with pharmaceutical firms, which is a characteristic revenue model for clinical-stage biotech developers.
XENE
Xenon Pharmaceuticals
$4.07Bn
41.39
+2.45%
+7.76%
Xenon Pharmaceuticals is a biopharmaceutical company focused on drug discovery and development of therapies for neurological and psychiatric disorders. Its revenue is currently generated through collaboration agreements, milestone payments, and potential royalties, specifically citing a license and collaboration agreement with Neurocrine Biosciences.
ABCL
AbCellera Biologics
$4.07Bn
12.46
-0.32%
+209.18%
AbCellera is a clinical-stage biotechnology company that researches and develops antibody medicines, including multispecific formats and antibody-drug conjugates. Its revenue model is based on biologic-focused partnership payments, milestones, and royalties from collaborators like Eli Lilly and Regeneron.
AMLX
Amylyx Pharmaceuticals
$3.97Bn
30.91
+2.32%
+153.78%
Amylyx is a clinical-stage company developing therapies derived from biological science, specifically antisense oligonucleotides like AMX0114 and GLP-1 receptor antagonists like avexitide. Its revenue model currently relies on collaborations and grants to fund the development of these biologic-based drug candidates.
BLRX
BioLineRx
$3.84Bn
1.47
-6.96%
-57.27%
BioLineRx is a biopharmaceutical company that researches and develops therapies derived from biological science, such as motixafortide (a CXCR4 antagonist) for stem-cell mobilization and oncology. Its revenue model is based on biologic product licensing, milestone payments, and royalties from partners like Ayrmid and Gloria.
ELVN
Enliven Therapeutics
$3.77Bn
51.20
-0.68%
+173.65%
Enliven Therapeutics is a clinical-stage company focused on the discovery and development of small molecule therapeutics, such as ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 inhibition. These are branded prescription drug candidates rather than biologics, placing the company in the Pharmaceuticals category.
LEGN
Legend Biotech
$3.76Bn
20.41
-15.97%
-35.39%
Legend Biotech focuses on the development and commercialization of CAR T therapies, specifically CARVYKTI for multiple myeloma, which are engineered cell therapies. The company's core platform involves proprietary llama-derived single-domain antibody technology and dual-binding CAR design to modify cells for oncology treatment.
IOVA
Iovance Biotherapeutics
$3.74Bn
8.08
-1.10%
+240.93%
Iovance develops and commercializes tumor infiltrating lymphocyte (TIL) cell therapies, specifically its lead product Amtagvi (lifileucel), which is an individualized T cell therapy. The company's core platform is based on cellular modification to harness a patient's own immune system to destroy cancer cells.
VKTX
Viking Therapeutics
$3.65Bn
28.66
-0.90%
-24.12%
Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically dual agonists like VK2735 (GLP-1 and GIP receptors) and thyroid hormone receptor beta agonists like VK2809. Its revenue model currently consists of collaboration agreements, licensing arrangements, and research funding typical of biotechnology developers.
OGN
Organon
$3.65Bn
13.89
+0.22%
+80.16%
Organon's primary revenue comes from the sale of branded prescription pharmaceuticals, specifically its Women's Health segment featuring products like Nexplanon and NuvaRing. The company markets these branded medicines across therapeutic areas including contraception, fertility, and cardiovascular health.
TARS
Tarsus Pharmaceuticals
$3.64Bn
73.83
+4.22%
+1.43%
Tarsus Pharmaceuticals develops and markets branded prescription drugs, specifically XDEMVY lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company generates the majority of its revenue from the sales of this branded pharmaceutical product to eye care professionals and patients.
VRDN
Viridian Therapeutics, Inc.DE
$3.50Bn
30.86
+2.22%
+11.61%
Viridian Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like veligrotug and elegrobart. Its product pipeline focuses on biology-based drug discovery for thyroid eye disease and autoimmune disorders.
GMAB
Genmab A
$3.47Bn
54.07
-3.12%
+86.06%
Genmab is a biotechnology company that develops and commercializes antibody-based therapies, such as epcotamab and tisotumab vedotin. Its revenue is derived from biologic product sales, royalties from partnered biologics like daratumumab and rybrevant, and milestone payments from collaborations with partners like AbbVie and BioNTech.
ARQT
Arcutis Biotherapeutics
$3.45Bn
27.39
+4.54%
+15.33%
Arcutis is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically targeting immune-mediated dermatological conditions. Its revenue is generated from the sales of ZORYVE products and collaboration/milestone payments from partners like Huadong and Sato.
SUPN
Supernus
$3.39Bn
28.75
+4.09%
—
Indivior develops and markets branded prescription pharmaceuticals, specifically SUBLOCADE and SUBOXONE Film, for the treatment of opioid use disorder. Its revenue is derived from the sale of these branded medications to healthcare providers, pharmacies, and distributors.
DYN
Dyne Therapeutics
$3.36Bn
17.92
-3.76%
-3.19%
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically using its FORCE platform to deliver oligonucleotides and enzymes. Its lead candidates, z-rostudirsen and z-basivarsen, are biologics targeting neuromuscular diseases like Duchenne muscular dystrophy and myotonic dystrophy type 1.
TAK
Takeda Pharmaceutical
$3.33Bn
20.91
-0.90%
+52.52%
Takeda is a global pharmaceutical company that develops and markets branded prescription drugs across multiple therapeutic areas. Its revenue is driven by branded products such as ENTYVIO for inflammatory bowel disease and VYVANSE for ADHD.
CELC
Celcuity
$3.29Bn
67.05
-4.72%
-12.58%
Celcuity is a clinical-stage biotechnology company developing gedatolisib, a targeted therapy for solid tumors. Its revenue model currently relies on collaboration payments and milestones from partners like Pfizer, which is characteristic of biology-based drug discovery and development.
IRON
Disc Medicine
$3.27Bn
84.64
+4.16%
+1.27%
Disc Medicine is a clinical-stage biopharmaceutical company developing therapies derived from biological science to treat hematologic diseases. Its revenue model currently relies on licensing agreements and milestone payments for candidates like bitopertin, DISC 0974, and DISC 0998.
TLX
Telix Pharmaceuticals
$3.20Bn
9.45
-4.45%
-6.25%
Telix is a biopharmaceutical company that develops and commercializes therapies and diagnostics derived from biological science, specifically antibody-based radiopharmaceuticals like Illuccix and Gozellix. Its core business involves the research and commercialization of biologic-based drug discovery for precision oncology.
DNLI
Denali Therapeutics
$3.18Bn
19.85
-2.50%
+27.24%
Denali Therapeutics is a biotechnology company developing therapies derived from biological science, specifically using its TransportVehicle platform to deliver antibodies, enzymes, and oligonucleotides. Its current revenue is derived from collaboration and milestone payments from partners like Biogen, Takeda, and Sanofi.
ACAD
Acadia Pharmaceuticals
$3.16Bn
18.28
+10.79%
-17.66%
Acadia Pharmaceuticals develops and markets branded prescription drugs, specifically NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. Its revenue is derived almost exclusively from the net product sales of these branded pharmaceuticals.
BHC
Bausch Health Companies
$3.10Bn
8.28
-1.43%
+29.37%
The company describes itself as a diversified specialty pharmaceutical company with significant revenue from generic and branded generic pharmaceuticals, as well as niche specialty products in gastroenterology and neuroscience.
IDYA
IDEAYA Biosciences
$3.07Bn
31.75
-0.87%
+2.78%
IDEAYA Biosciences is a precision medicine oncology company that researches and develops therapies derived from biological science, including antibody-drug conjugates (ADCs) like IDE849 and IDE034. Its revenue model consists of upfront payments, milestone payments, and royalties from collaborations with partners such as Servier and Novartis, which is characteristic of biotechnology developers.
AXGN
2nd
Axogen
$3.04Bn
50.89
+0.49%
+112.04%
The company develops and commercializes the Avance Nerve Graft, which is a biologically active nerve allograft. This biologic product is approved under the FDA's Section 351 pathway for bridging peripheral nerve discontinuities.
VCEL
Vericel
$3.01Bn
59.03
+1.10%
+51.40%
Vericel's core business is the development and commercialization of autologous cell therapies, specifically MACI for cartilage repair and Epicel for severe burns. These products involve the modification and application of a patient's own cells, which aligns directly with the Gene and Cell Therapy classification.
RADX
Radiopharm Theranostics
$3.01Bn
0.85
-3.41%
-82.86%
Radiopharm Theranostics develops therapies derived from biological science, specifically using monoclonal antibodies, nanobodies, and peptides (e.g., Nano-mAbs and PSA-mAb segments). Its revenue model consists of collaboration payments, milestones, and royalties, which is characteristic of biotechnology developers.
ZLAB
Zai Lab
$2.97Bn
26.43
-1.60%
+20.74%
Zai Lab is a biopharmaceutical company that commercializes therapies derived from biological science, including antibody-drug conjugates like Zoci (ZL-1310) and biologics such as VYVGART and VYVGART Hytrulo. Its revenue is derived from the sales of these innovative biologic products and its pipeline focuses on biology-based drug discovery.
XNCR
Xencor
$2.94Bn
39.39
+2.07%
+186.68%
Xencor is a clinical-stage biopharmaceutical company that develops engineered antibody therapeutics, specifically using its XmAb platform to create bispecific antibodies and recombinant proteins. Its revenue is derived from biologic product collaborations, milestone payments, and royalties from marketed medicines like Monjuvi and Ultomiris.
XERS
Xeris Biopharma Holdings
$2.89Bn
15.83
-0.19%
+105.05%
Xeris Biopharma develops and markets branded prescription drugs such as Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for Primary Periodic Paralysis. Its revenue is generated through the sale of these branded pharmaceutical products to patients via healthcare provider prescriptions.
ADMA
Adma Biologics
$2.82Bn
12.67
-0.94%
-13.87%
Adma Biologics is a biopharmaceutical company that develops and manufactures biologics derived from human plasma, specifically immune globulin products like ASCENIV, BIVIGAM, and Nabi HB. Its core revenue is derived from the sale of these biologic therapies used to treat immunodeficient patients.
MBX
MBX Biosciences
$2.80Bn
56.33
+4.20%
+130.01%
MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapies, such as the GLP 1/GIP co agonist MBX 4291 and the parathyroid hormone prodrug canvuparatide. These are biological science-derived therapies (peptides) developed using its proprietary PEP platform.
HCM
HUTCHMED (China)
$2.68Bn
15.38
+0.39%
+1.92%
HUTCHMED is a biopharmaceutical company focused on the discovery and development of targeted therapies and immunotherapies, such as savolitinib and fruquintinib. Its revenue is derived from the sale of these biologic-focused oncology drugs and milestone payments from partners like AstraZeneca and Eli Lilly.
BEAM
Beam Therapeutics
$2.60Bn
25.15
-6.92%
+16.17%
Beam Therapeutics focuses on precision genetic medicines using a proprietary base editing technology to modify DNA. The company develops therapies for genetic disorders such as sickle cell disease and alpha 1 antitrypsin deficiency, which fits the core platform of genetic modification described in H-03.
RGC
Regencell Bioscience Holdings
$2.59Bn
5.23
-6.94%
-62.18%
Regencell Bioscience Holdings focuses on the research, development, and commercialization of a standardized Traditional Chinese Medicine (TCM) formula for the treatment of ADHD and ASD. The company intends to generate revenue from the sale of these branded pharmaceutical products once they receive regulatory approval.
NEOG
2nd
Neogen
$2.55Bn
11.67
-3.39%
+83.49%
The Animal Safety segment (28.7% of sales) develops and markets veterinary pharmaceuticals, vaccines, and diagnostic products for livestock producers, veterinarians, and companion animal owners.
SEPN
Septerna
$2.49Bn
52.34
+3.15%
+189.17%
Septerna is a clinical-stage biotechnology company that uses its proprietary Native Complex Platform to research and develop therapies derived from biological science, specifically targeting G protein coupled receptors. Its revenue is generated through collaboration agreements, upfront payments, and potential milestones with pharmaceutical partners like Novo Nordisk.
PVLA
Palvella Therapeutics
$2.47Bn
168.71
-3.08%
+110.13%
Palvella Therapeutics is a biopharmaceutical company developing branded prescription topical therapies, such as QTORIN rapamycin and QTORIN pitavastatin, for rare skin diseases. These are small-molecule active ingredients (rapamycin and pitavastatin) formulated into gels, fitting the profile of branded pharmaceutical development.
CLDX
Celldex Therapeutics
$2.41Bn
30.65
-1.89%
+35.20%
Celldex Therapeutics is a biopharmaceutical company focused on developing therapies derived from biological science, specifically monoclonal and bispecific antibodies like barzolvolimab and CDX-622. Its revenue model currently consists of partnership agreements, licensing arrangements, and milestone payments from collaborators, which is characteristic of clinical-stage biotechnology developers.
RCUS
Arcus Biosciences
$2.38Bn
18.67
-1.37%
-4.06%
Arcus Biosciences is a biopharmaceutical company developing therapies derived from biological science, specifically antibody therapies like domvanalimab and zimberelimab. Its revenue model currently relies on collaboration and licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
CURLF
2nd
Curaleaf Holdings
$2.36Bn
8.91
-1.00%
+1.02%
Curaleaf operates pharma-grade manufacturing facilities in Europe (Germany, Spain, Canada, Portugal, and the UK) that produce cannabinoid-based pharmaceutical products for medical use.
NAMS
NewAmsterdam Pharma
$2.30Bn
19.18
+1.05%
-50.78%
NewAmsterdam Pharma is developing obicetrapib, a branded prescription drug for cardiometabolic diseases and Alzheimer's. The company plans to commercialize this small-molecule CETP inhibitor independently in the US and via licensing in Europe, generating revenue from direct sales, milestone payments, and royalties.
BHVN
Biohaven
$2.28Bn
15.10
-0.26%
+93.84%
Biohaven is a clinical-stage biopharmaceutical company developing therapies derived from biological science, including antibody-drug conjugates (ADCs) like BHV-1510 and BHV-1530 in its oncology segment. Its business model focuses on biology-based drug discovery and development across immunology, neuroscience, and oncology.
ZYME
Zymeworks
$2.24Bn
31.46
+2.11%
+74.29%
Zymeworks is a biotechnology company that develops therapies derived from biological science, specifically multispecific antibodies and antibody-drug conjugates like ZW191 and ZW220. Its revenue is derived from biologic product collaborations, milestone payments, and royalties from partners such as Jazz Pharmaceuticals and BeOne.
VIR
Vir Biotechnology
$2.23Bn
13.15
-3.66%
+144.88%
Vir Biotechnology is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody combinations and T cell engagers. Its revenue is currently generated through collaboration and licensing agreements, milestone payments, and royalties, which is characteristic of the Biotechnology industry.
PHVS
Pharvaris
$2.22Bn
33.99
-1.39%
+50.20%
Pharvaris is a biopharmaceutical company developing deucrictibant, a novel oral therapy targeting the bradykinin B2 receptor for rare diseases. Its business model is centered on the research, development, and planned commercialization of these biological-science-based therapies.
REPL
Replimune
$2.21Bn
23.28
+4.58%
+167.28%
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies derived from an engineered strain of herpes simplex virus 1 (HSV-1). Its product candidates, such as RP1 and RP2, are biologics designed to selectively replicate in tumors and stimulate immune responses.
IMNM
Immunome
$2.20Bn
18.65
-3.67%
+13.44%
Immunome is a clinical-stage biotechnology company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like IM-1021 and radioligand therapies like IM-3050. Its revenue model is based on strategic partnerships, licensing agreements, and milestone payments typical of biotech developers.
LKFT
Lakefront Biotherapeutics
$2.20Bn
33.41
-0.33%
+2.96%
Galapagos NV is a biotechnology company that researches and develops therapies for immunology and oncology, generating revenue from collaboration payments and royalties. Its business model focuses on biology-based drug discovery and development, as evidenced by its pipeline of therapeutic programs.
AUPH
Aurinia Pharmaceuticals
$2.18Bn
16.30
-1.93%
+9.47%
Aurinia Pharmaceuticals develops and markets branded prescription drugs, specifically its flagship oral therapy LUPKYNIS for lupus nephritis. The company generates the majority of its revenue from the direct sale of this branded pharmaceutical product in the U.S. and through royalties and supply agreements internationally.
VERA
Vera Therapeutics
$2.17Bn
30.03
-1.89%
+8.22%
Vera Therapeutics is a biotechnology company developing therapies derived from biological science, specifically atacicept, which is a human TACI Fc fusion protein. The company also develops MAU868, a monoclonal antibody, both of which are biologic-based drug candidates.
SDGR
2nd
Schrodinger
$2.13Bn
32.41
-2.94%
+77.20%
The company operates a Drug Discovery segment where it develops a proprietary pipeline of therapeutic candidates and conducts collaborative research with biopharma partners, earning revenue from milestones and royalties.
TRVI
Trevi Therapeutics
$2.13Bn
14.91
-2.61%
+27.76%
Trevi Therapeutics is a clinical-stage company developing Haduvio (oral nalbuphine ER), which is a small-molecule branded prescription drug candidate for chronic cough. The company's focus is on the discovery and development of this branded pharmaceutical therapy for patients with idiopathic pulmonary fibrosis and refractory cough.
MAZE
Maze Therapeutics
$2.00Bn
35.45
+1.55%
+16.27%
Maze Therapeutics is a clinical-stage biopharmaceutical company that uses its proprietary Compass platform for biology-based drug discovery and development. It develops therapies derived from human genetics and functional genomics, such as the APOL1 inhibitor MZE829 and the SLC6A19 inhibitor MZE782, and generates revenue through milestone payments and royalties from biotechnology partners.
RXRX
Recursion Pharmaceuticals
$1.99Bn
3.55
-6.82%
-21.29%
Recursion is a clinical-stage biotechnology company that researches and develops therapies using a proprietary drug discovery platform. Its revenue is derived from collaboration and milestone payments from pharmaceutical partners like Roche, Genentech, and Sanofi.
HRMY
Harmony Biosciences Holdings
$1.97Bn
33.55
-0.68%
+5.44%
Harmony Biosciences discovers, develops, and markets branded prescription drugs for rare neurological diseases, with the vast majority of its revenue coming from the sale of its branded product WAKIX (pitolisant). The company's business model is centered on branded pharmaceutical sales to specialty pharmacies and distributors.
SLBT
SL Science Holding
$1.96Bn
0.90
-8.16%
-91.34%
The company specializes in developing innovative cellular and gene therapies, specifically CD-19 Armed-T and Gamma Delta T cell therapies for blood, pancreatic, and brain cancers. Its core business model centers on advancing regenerative medicine and immuno-oncology through these cell-based platforms.
ETON
Eton Pharmaceuticals
$1.95Bn
67.54
+4.96%
+299.17%
Eton Pharmaceuticals develops and markets branded prescription drugs for rare diseases, such as INCRELEX for insulin-like growth factor 1 deficiency and GALZIN for Wilson disease. Its revenue is derived from the sale of these branded pharmaceutical products to healthcare providers and patients.
ZBIO
Zenas BioPharma
$1.94Bn
28.58
+0.04%
-11.98%
Zenas BioPharma is a clinical-stage biopharmaceutical company focusing on therapies derived from biological science, specifically monoclonal antibodies like obexelimab. Its revenue model currently consists of upfront licensing payments, milestone payments, and royalties from partners such as Bristol Myers Squibb and InnoCare.
BCRX
Biocryst Pharmaceuticals
$1.93Bn
7.53
-1.05%
+4.58%
BioCryst is a biotechnology company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Navenibart and STAR-0310, and protein therapeutics like BCX17725. Its revenue model includes biologic product sales, licensing agreements, and milestone payments from collaborators such as Torii Pharmaceutical and Shionogi.
AGIO
Agios Pharmaceuticals
$1.90Bn
31.76
+1.21%
-23.25%
Agios is a biopharmaceutical company that leverages expertise in cellular metabolism to develop therapies for rare diseases, such as PYRUKYND® and AQVESME™. Its revenue is derived from the sale of these biologic-focused medicines, as well as milestone payments and royalties from licensing arrangements like the AG 236 siRNA program.
TRAX
First Tracks Biotherapeutics
$1.88Bn
52.33
+5.14%
—
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing monoclonal antibodies, such as rosnilimab and ANB033, which are therapies derived from biological science. Its business model focuses on the research and development of these biologics for autoimmune and inflammatory diseases.
KLRA
Kailera Therapeutics
$1.85Bn
14.24
+3.94%
—
Kailera Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically GLP-1 GIP dual and triple agonists like ribupatide. Its revenue model currently consists of collaboration payments, technology transfer fees, and potential milestones from Jiangsu Hengrui Pharmaceuticals.
MESO
Mesoblast
$1.81Bn
13.99
-3.12%
-8.02%
Mesoblast develops allogeneic cellular medicines using a proprietary mesenchymal lineage cell therapy platform to create off-the-shelf therapies. Its lead product, Ryoncil, is a mesenchymal stromal cell therapy approved for pediatric graft versus host disease.
COAG
Hemab Therapeutics Holdings
$1.81Bn
38.77
-9.67%
—
Hemab Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically antibodies such as sutacimig and HMB 002. These assets are monoclonal antibodies targeting Factor VII, TLT1, and von Willebrand factor to treat rare bleeding disorders.
GENB
Generate Biomedicines
$1.77Bn
13.78
-2.82%
—
Generate Biomedicines is a clinical-stage company that develops therapies derived from biological science, specifically monoclonal antibodies and cytokine engineered therapies. Its revenue model is based on strategic collaboration agreements with pharmaceutical partners like Amgen and Novartis, involving up-front payments, milestones, and royalties.
STOK
Stoke Therapeutics
$1.76Bn
27.21
-1.80%
+21.64%
Stoke Therapeutics develops RNA-based medicines, specifically antisense oligonucleotides (ASOs), which are categorized as oligonucleotide medicines under Biotechnology. The company's revenue is derived from collaboration and milestone payments from partners like Acadia Pharmaceuticals and Biogen, typical for clinical-stage biotech developers.
SRPT
Sarepta Therapeutics
$1.76Bn
16.42
-4.76%
-4.92%
Sarepta's core business is the development and commercialization of genetic modalities, specifically gene therapy as evidenced by its product ELEVIDYS and its use of the AAVrh.74 vector. The company focuses on modifying or replacing genes to treat rare diseases like Duchenne muscular dystrophy.
NRIX
Nurix Therapeutics
$1.73Bn
15.88
-1.61%
+29.63%
Nurix Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation medicines. Its revenue is derived from collaboration and milestone payments from partners like Gilead, Sanofi, and Pfizer, and it focuses on biology-based drug discovery using its DEL-AI platform.
BFLY
2nd
Butterfly Network
$1.73Bn
6.50
-2.40%
+192.79%
The company has a dedicated business line for animal health, selling the Butterfly iQ Vet line specifically to veterinarians and veterinary practices.
ABSI
Absci
$1.71Bn
9.97
-7.51%
+200.30%
Absci is a clinical-stage biopharmaceutical company that researches and develops antibody-based therapeutics, such as ABS-201, using biological science. Its revenue model includes the development of its own pipeline and receiving milestone payments and royalties from biologic product collaborations.
ANIP
Ani Pharmaceuticals
$1.70Bn
71.25
+5.10%
-19.88%
ANI Pharmaceuticals focuses on specialty and generic drugs, offering over 120 generic products across various dosage forms. Its 'Generics and Other' segment specifically targets niche opportunities such as paragraph IV filings and competitive generic therapy designations.
SLS
SELLAS Life Sciences
$1.69Bn
8.37
-2.45%
+458.00%
SELLAS is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically galinpepimut S, a peptide immunotherapy. Its revenue is currently generated through milestone and royalty payments from collaboration agreements, such as the one with 3D Medicines.
NVAX
Novavax
$1.68Bn
10.20
-6.34%
+43.46%
Novavax is a biotechnology company that develops therapies derived from biological science, specifically using a recombinant nanoparticle vaccine technology and a baculovirus insect cell expression system. Its revenue is generated from the sale of its COVID-19 vaccine (Nuvaxovid) and milestone payments from collaborations with partners like Sanofi and Pfizer.
IMCR
Immunocore Holdings
$1.67Bn
32.38
+2.15%
-7.49%
Immunocore is a biotechnology company that develops therapies derived from biological science, specifically using its ImmTAX platform to engineer T-cell receptors. It generates revenue from the sale of KIMMTRAK (tebentafusp), a biologic product used to treat uveal melanoma.
RARE
Ultragenyx Pharmaceutical
$1.64Bn
16.14
-1.65%
-49.47%
Ultragenyx is a biopharmaceutical company that develops and commercializes therapies derived from biological science, including biologics and enzyme replacement therapies like Mepsevii. Its revenue is generated from the sale of these biologic products and through collaboration agreements and milestone payments with partners such as Kyowa Kirin and Regeneron.
PGEN
Precigen
$1.62Bn
4.52
-4.44%
+13.00%
Precigen's core business is the development and commercialization of gene and cell therapies, utilizing its proprietary AdenoVerse and Ultra CAR T platforms. Its lead approved product, Papzimeos, and its pipeline targeting cancers (PRGN 2009, 3005, 3006, 3007) are based on genetic and cellular modification.
NBTX
Nanobiotix
$1.59Bn
32.87
+2.62%
+48.26%
Nanobiotix is a clinical-stage biotechnology company developing nanotherapeutics, such as the hafnium oxide-based nanoparticle JNJ-1900 (NBTXR3). Its revenue model is based on biotechnology-typical sources, including strategic collaborations, licensing agreements, and milestone payments from partners like Janssen Pharmaceutica NV.
QURE
uniQure
$1.59Bn
22.71
-0.35%
-13.15%
uniQure is a clinical-stage gene therapy company that uses a proprietary adeno-associated virus (AAV) vector platform to develop treatments for genetic diseases. Its pipeline includes gene-based therapies such as AMT-130 for Huntington's disease and AMT-191 for Fabry disease, and it earns revenue from royalties on the gene therapy HEMGENIX.
JAZZ
Jazz Pharmaceuticals
$1.58Bn
245.43
+0.78%
+84.27%
Jazz Pharmaceuticals develops and markets branded prescription drugs for rare diseases, including Xywav for sleep disorders, Epidiolex for epilepsies, and Zepzelca for oncology. Its revenue is primarily generated through net product sales of these specialized, branded medications.
NTLA
Intellia Therapeutics
$1.57Bn
11.17
-7.61%
+14.80%
Intellia Therapeutics is a clinical-stage company focused on developing CRISPR-based therapies, specifically utilizing a proprietary CRISPR/Cas9 platform for in vivo and ex vivo gene editing. Its lead programs, lonvo-z and nex-z, are designed to modify genes to treat hereditary angioedema and transthyretin amyloidosis.
ALVO
Alvotech
$1.52Bn
4.88
+4.05%
-10.95%
Alvotech is focused solely on the development and manufacture of biosimilar medicines, which are specifically categorized under H-04. The company's revenue is derived from the sale of these biosimilars and licensing income from partners like Teva and STADA.
DMRA
Damora Therapeutics
$1.49Bn
24.15
+0.33%
+40.00%
Damora Therapeutics is a biopharmaceutical company developing monoclonal antibodies, specifically DMR-001, DMR-002, and DMR-003, to treat hematologic disorders. These are therapies derived from biological science targeting the mutant calreticulin protein (mutCALR), which fits the definition of biotechnology.
PCRX
Pacira BioSciences
$1.46Bn
36.49
+0.08%
+58.17%
The company's primary revenue is derived from branded prescription pharmaceuticals, specifically EXPAREL (a long-acting local analgesic) and ZILRETTA (an extended-release corticosteroid), which together account for the vast majority of its total revenue.
NUVB
Nuvation Bio
$1.46Bn
4.20
-3.23%
-9.48%
Nuvation Bio develops and markets branded prescription oncology drugs, specifically the FDA-approved IBTROZI for ROS1 positive non small cell lung cancer. Its revenue is generated through direct product sales in the US and licensing/royalties from partners like Eisai and Nippon Kayaku.
OCUL
Ocular Therapeutix
$1.45Bn
6.61
-3.50%
-38.97%
Ocular Therapeutix is a biopharmaceutical company utilizing its proprietary ELUTYX hydrogel technology platform to develop therapies. Its revenue is derived from the sale of DEXTENZA, a corticosteroid insert, and milestone payments from collaborations for biologic-based delivery systems.
TYRA
Tyra Biosciences
$1.45Bn
21.00
-5.83%
+44.83%
Tyra Biosciences is a clinical-stage biotechnology company that uses its proprietary SNÅP platform to research and develop therapies derived from biological science, specifically small molecule inhibitors targeting FGFR signaling. Its pipeline includes candidates like dabogratinib for urothelial carcinoma and achondroplasia, and TYRA-430 for hepatocellular carcinoma.
LBRX
Lb Pharmaceuticals
$1.45Bn
44.94
-0.40%
+207.60%
Lb Pharmaceuticals is developing LB 102, a branded prescription drug candidate for neuropsychiatric disorders like schizophrenia and bipolar depression. The company expects future revenue from the commercial sale of oral and long-acting injectable formulations of this branded pharmaceutical to healthcare providers and patients.
AAPG
Ascentage Pharma Group International
$1.42Bn
15.20
-1.17%
-53.09%
Ascentage Pharma is a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically targeting apoptotic pathways and tyrosine kinase signaling. Its lead assets, Olverembatinib and Lisaftoclax, are developed using a proprietary drug discovery platform focused on biological targets in hematological malignancies.
KRSA
Korsana Biosciences
$1.42Bn
31.11
+0.42%
+146.90%
Cyclerion is a biopharmaceutical company focused on developing therapies for neuropsychiatric disorders, specifically its candidate CYC 126 for treatment-resistant depression. Its current revenue is derived from licensing agreements and milestone payments associated with its sGC portfolio, such as the agreement with Akebia for praliciguat.
PAHC
Phibro Animal Health
$1.41Bn
34.64
+0.09%
-24.42%
The company's primary business is the development, manufacture, and marketing of animal health products, including antibacterials, anticoccidials, vaccines, and vaccine adjuvants for poultry, swine, beef, dairy cattle, and aquaculture.
ANAB
Anaptysbio
$1.40Bn
48.38
+0.85%
+113.60%
Anaptysbio is a clinical-stage biotechnology company developing antibody-based therapeutics such as rosnilimab, ANB033, and ANB101. Its revenue is derived from biologic-related sources including milestone payments and royalties from collaborations with GSK and Vanda.
TSHA
Taysha Gene Therapies
$1.39Bn
4.28
-2.06%
+10.03%
Taysha Gene Therapies is a clinical-stage company developing adeno-associated virus (AAV)-based gene therapies, specifically TSHA-102 for Rett syndrome. Its core platform involves modifying genes to treat monogenic diseases of the central nervous system, which aligns directly with the Gene and Cell Therapy classification.
MLYS
Mineralys Therapeutics
$1.37Bn
15.52
-1.83%
-65.12%
Mineralys Therapeutics is developing lorundrostat, an oral aldosterone synthase inhibitor, which is a branded prescription drug candidate for hypertension and cardiorenal conditions. The company's core business is the discovery and development of this small-molecule pharmaceutical to treat diseases driven by dysregulated aldosterone.
INVA
Innoviva
$1.36Bn
19.08
+0.42%
-8.58%
Innoviva develops and commercializes a portfolio of branded prescription therapeutics for critical care and infectious diseases, including GIAPREZA, XACDURO, XERAVA, and ZEVTERA. It also earns significant revenue from branded respiratory products developed in collaboration with GSK.
MNKD
Mannkind
$1.36Bn
4.23
+1.20%
-21.96%
MannKind is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically inhaled insulin (Afrezza) and inhaled treprostinil (Tyvaso DPI). Its revenue is driven by the sale of these biologic products and royalties from collaborations with partners like United Therapeutics.
OKYO
OKYO Pharma
$1.35Bn
1.38
+7.81%
-48.70%
OKYO Pharma is a clinical-stage biopharmaceutical company developing urcosimod, which is described as a lipidated peptide. This falls under the biotechnology category as it involves therapies derived from biological science (peptides) and the company's revenue model relies on milestone payments and potential biologic product sales.
INBX
Inhibrx Biosciences
$1.33Bn
90.61
-1.23%
+14.70%
Inhibrx is a clinical-stage biopharmaceutical company developing biologic therapeutics, specifically multi-specific biologics and agonists like ozekibart and INBRX 106. Its revenue model is based on potential milestone and royalty payments from collaborations, which is characteristic of biotechnology developers.
CMPS
COMPASS Pathways
$1.31Bn
9.25
+0.65%
+61.15%
Compass Pathways is a clinical-stage biotechnology company developing COMP360, a proprietary formulation of psilocybin for treatment-resistant depression and PTSD. Its business model focuses on biology-based drug discovery and development, currently financing operations through equity and collaboration agreements while conducting Phase 2b and Phase 3 clinical trials.
OPK
Opko Health
$1.27Bn
1.71
+0.00%
+28.57%
The company develops, manufactures, and markets branded prescription drugs such as the growth hormone NGENLA and the kidney disease treatment Rayaldee. It generates significant revenue from direct sales of these branded pharmaceuticals and royalty payments from partners like Pfizer.
NKTR
Nektar Therapeutics
$1.25Bn
37.78
-0.13%
-34.83%
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically immunomodulatory agents and biologics like NKTR-255 targeting the IL-15 pathway. Its revenue model is based on collaboration agreements, royalties, and milestone payments from partnered drug programs.
RAPP
Rapport Therapeutics
$1.25Bn
25.96
-0.42%
+4.17%
Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule precision medicines, such as its lead candidate RAP 219, for neurological and psychiatric disorders. Its business model relies on its RAP technology platform for biology-based drug discovery and development.
URGN
UroGen Pharma
$1.24Bn
25.32
-3.84%
+9.47%
UroGen Pharma is described as a biotechnology company that develops therapies derived from biological science, specifically utilizing its proprietary RTGel reverse thermal hydrogel platform. Its revenue is generated from the sale of biologic-based products like Jelmyto and Zusduri, as well as potential milestone payments and royalties from licensing agreements.
AMPH
Amphastar Pharmaceuticals
$1.24Bn
29.06
-1.09%
+11.26%
Amphastar primarily develops, manufactures, and commercializes technically challenging generic injectable, inhalation, and intranasal products. Its revenue is driven by the sale of these generic and specialty pharmaceuticals to hospitals, clinics, and pharmacies.
GHRS
GH Research
$1.21Bn
19.56
+1.56%
+44.46%
GH Research is a clinical-stage biopharmaceutical company developing mebufotenin-based therapies, such as GH001 and GH002, for psychiatric and neurological disorders. Its business model focuses on biology-based drug discovery and development for treatment-resistant depression.
VOR
Vor Biopharma
$1.20Bn
19.56
-2.10%
+4.04%
Vor Biopharma is a clinical-stage biopharmaceutical company developing telitacicept, which is described as a recombinant fusion protein. This biology-based drug discovery and development for autoimmune diseases fits the Biotechnology classification.
SPTX
Seaport Therapeutics
$1.18Bn
21.97
+0.23%
—
Seaport Therapeutics is a clinical-stage company developing branded prescription medicines for neuropsychiatric disorders, such as GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder. Its business model focuses on creating new composition of matter intellectual property for branded pharmaceutical sales.
ANRO
Alto Neuroscience
$1.14Bn
28.60
+2.88%
+124.49%
Alto Neuroscience is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric disorders such as major depressive disorder and schizophrenia. Its revenue model currently consists of upfront fees, milestone payments, and royalties from collaborations with partners like Sanofi and Cerecor, which is characteristic of biotechnology developers.
SGP
SpyGlass Pharma
$1.14Bn
34.18
-10.92%
—
SpyGlass Pharma is a biopharmaceutical company developing branded prescription drug delivery systems, specifically the BIM IOL System and BIM DRS, to treat glaucoma and ocular hypertension using the drug bimatoprost. Its revenue model is based on the sale of these branded pharmaceutical products and associated reimbursement for the physician-administered drug component.
HROW
Harrow
$1.14Bn
30.36
+10.52%
-11.07%
Harrow develops and markets a wide range of FDA-approved branded ophthalmic pharmaceuticals, such as IHEEZO, VEVYE, and VIGAMOX. Its primary revenue is generated from the sale of these branded prescription products for conditions like dry eye and glaucoma.
SVRA
Savara
$1.09Bn
4.92
-2.57%
+23.00%
Savara is a clinical-stage biopharmaceutical company developing molgramostim inhalation solution (MOLBREEVI), which is described as an inhaled biologic delivering recombinant human granulocyte macrophage colony stimulating factor. This fits the H-02 classification for companies researching and developing therapies derived from biological science, such as recombinant proteins.
SLDB
Solid Biosciences
$1.08Bn
7.17
+2.14%
+72.77%
Solid Biosciences focuses on developing gene therapy candidates using adeno-associated virus (AAV) to deliver functional genes for diseases like Duchenne muscular dystrophy and Friedreich's ataxia. Its core platform is based on genetic modification and proprietary capsid technology for vector delivery.
MLTX
MoonLake Immunotherapeutics
$1.07Bn
12.56
-0.48%
+16.08%
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing Nanobody-based treatments, which are biological therapies. Its primary asset, SLK, is a tri-specific Nanobody designed to inhibit IL-17A and IL-17F cytokines for inflammatory diseases.
JBIO
Jade Biosciences
$1.04Bn
16.40
+5.13%
+76.72%
Jade Biosciences is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies, such as JADE101 and JADE201, which are biologics. Its business model focuses on the research and development of these biological therapies for autoimmune diseases.
DBVT
DBV Technologies
$1.04Bn
11.51
+4.16%
-15.24%
DBV Technologies is a biopharmaceutical company developing therapies derived from biological science, specifically epicutaneous immunotherapy (EPIT) using the Viaskin patch for peanut and cow's milk allergies. Its revenue model currently relies on collaboration agreements, licensing, and milestone payments from partners like Nestlé Health Science.
BRVE
Braveheart Bio
$1.02Bn
19.62
+0.82%
—
Braveheart Bio is developing BHB-1893, which is described as an oral small-molecule cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. As a developer of branded small-molecule prescription pharmaceuticals, it fits the Pharmaceuticals classification.
ODTX
Odyssey Therapeutics
$958.81Mn
20.00
+4.44%
—
Odyssey Therapeutics is a biopharmaceutical company developing branded prescription small-molecule drugs, such as the RIPK2 inhibitor OD-001 and the SLC15A4 inhibitor OD-002. Its lead programs are oral small molecules targeting autoimmune and inflammatory diseases, which aligns with the Pharmaceuticals classification for branded small-molecule drug developers.
CRVS
Corvus Pharmaceuticals
$958.71Mn
11.37
+0.18%
+43.74%
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like mupadolimab. Its revenue model currently relies on collaboration, milestone payments, and royalties, which is characteristic of biotechnology developers.
CLYM
Climb Bio
$939.56Mn
11.74
+6.53%
+552.22%
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibodies, specifically budoprutug (anti-CD19) and CLYM116 (anti-APRIL). Its revenue is derived from collaboration agreements, milestone payments, and royalties, which is characteristic of the H-02 Biotechnology industry.
SLN
Silence Therapeutics
$935.01Mn
19.79
+0.20%
+211.65%
Silence Therapeutics is a biotechnology company that develops therapies derived from biological science, specifically using siRNA and its proprietary mRNAi GOLD™ platform to target messenger RNA. Its revenue is currently derived from collaboration and milestone payments from pharmaceutical partners like AstraZeneca and Hansoh for its RNAi-based drug candidates.
AKTS
Aktis Oncology
$932.64Mn
17.45
+6.86%
—
Aktis Oncology is a clinical-stage biotechnology company developing therapies derived from biological science, specifically a proprietary miniprotein radioconjugate platform. Its revenue is currently derived from collaboration agreements, license arrangements, and milestone payments from partners like Eli Lilly.
PHAR
Pharming
$927.62Mn
13.22
+0.46%
-24.67%
Pharming is a biotechnology company that develops and commercializes therapies derived from biological science, specifically RUCONEST®, which is a recombinant C1 esterase inhibitor protein replacement therapy. Its revenue is generated from the sale of these biologic products for rare and ultra-rare diseases.
ORIC
Oric Pharmaceuticals
$923.40Mn
8.91
-3.47%
-28.49%
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting PRC2 dysregulation and EGFR exon 20 mutations. Its revenue is currently derived from upfront payments, milestone payments, and royalties from licensing and collaboration agreements, which is characteristic of the Biotechnology industry.
MGTX
MeiraGTx Holdings
$906.09Mn
9.62
+1.37%
+12.51%
MeiraGTx is a clinical stage genetic medicines company developing gene therapies for disorders such as Parkinson's disease and inherited retinal diseases. Its core technology involves the delivery of genetic medicines and a proprietary riboswitch platform for controlling gene expression.
GLUE
Monte Rosa Therapeutics
$897.23Mn
10.50
-0.76%
-25.32%
Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically molecular glue degraders. Its revenue is currently derived from collaboration and milestone payments from partners like Novartis and Roche, which is characteristic of the H-02 classification.
STTK
Shattuck Labs
$888.64Mn
4.85
-2.81%
+156.61%
Shattuck Labs is a clinical-stage biotechnology company developing monoclonal and bispecific antibodies, such as SL-325 and SL-425, which are biologic therapies. Its revenue model is typical for biotech, relying on equity financing and potential collaboration payments and royalties.
FDMT
4D Molecular Therapeutics
$875.59Mn
12.46
-0.16%
+22.52%
The company focuses on developing genetic medicines using a proprietary Therapeutic Vector Evolution platform to create adeno-associated virus (AAV) vectors. Its product candidates, such as 4D-150 for retinal diseases and 4D-710 for cystic fibrosis, are designed to deliver transgenes to modify or replace genetic function.
PBLS
Parabilis Medicines
$867.83Mn
30.02
-1.15%
—
Parabilis Medicines is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically stabilized helical peptides created via its proprietary Helicon platform. Its lead candidate, zolucatetide, and its degrader programs for ERG and AR ON are biology-based drug discovery efforts targeting intracellular protein surfaces.
IMTX
Immatics
$860.74Mn
6.42
-0.16%
-28.90%
Immatics is a clinical-stage company developing T cell receptor (TCR) based immunotherapies, specifically autologous engineered T cell therapies (ACTengine) and bispecific molecules. Its core platform focuses on genetic and cellular modification to target intracellular cancer antigens in solid tumors.
SNDX
Syndax Pharmaceuticals
$854.00Mn
9.49
-0.63%
-39.63%
Syndax is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically monoclonal antibodies like Niktimvo (axatilimab). Its revenue is generated from the sales of these biologic products, as well as collaboration milestones and royalties.
LXRX
Lexicon Pharmaceuticals
$831.26Mn
1.86
+2.20%
+30.99%
Lexicon is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs, specifically commercializing INPEFA for heart failure. Its revenue is derived from the sales of this branded pharmaceutical product and licensing agreements for other small-molecule drug candidates.
RIGL
Rigel Pharmaceuticals
$826.82Mn
43.91
+4.42%
+27.09%
Rigel is described as a biotechnology company that develops therapies derived from biological science, specifically targeting signaling pathways for hematologic disorders and cancer. Its revenue is derived from the sale of biologic-based products like TAVALISSE, REZLIDHIA, and GAVRETO, as well as collaboration and milestone payments.
VSTM
Verastem
$824.71Mn
8.73
+0.34%
+5.82%
Verastem discovers, develops, and markets branded prescription drugs, specifically the AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated recurrent low-grade serous ovarian cancer. Its revenue is derived principally from the sales of this branded pharmaceutical product in the United States.
MANE
Veradermics
$822.06Mn
148.63
+3.39%
—
Veradermics is developing VDPHL01, an oral extended-release formulation of minoxidil, which is a branded prescription drug for pattern hair loss. The company intends to generate revenue from prescriptions written by dermatologists and primary care physicians.
ANNX
Annexon
$803.12Mn
4.21
-0.47%
+41.28%
Annexon is a biopharmaceutical company developing targeted immunotherapies, specifically complement protein C1q inhibitors, which are biological therapies. The company is a clinical-stage developer with no current product revenue, focusing on biological science to treat neuroinflammatory diseases.
ALMS
Alumis
$796.45Mn
6.40
-2.29%
+26.73%
Alumis is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies like lonigutamab and targeted inhibitors for immune-mediated diseases. Its business model focuses on biology-based drug discovery and development using a precision data analytics platform integrating genomic and proteomic information.
IRWD
Ironwood Pharmaceuticals
$796.30Mn
4.81
+2.78%
+90.12%
Ironwood Pharmaceuticals is described as a biotechnology company that develops therapies derived from biological science, specifically mentioning apraglutide, which is a peptide analog. Its revenue model includes biologic product sales, royalties, and milestone payments from partners like AstraZeneca and Astellas.
AURA
Aura Biosciences
$796.17Mn
7.65
-0.13%
+38.59%
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a virus-like drug conjugate (VDC) derived from biological science for targeted cancer therapy. Its revenue model is based on the development of these biologic candidates and potential future milestone payments or royalties.
IVA
Inventiva
$763.29Mn
3.95
+2.86%
+5.33%
Inventiva is a clinical-stage company developing lanifibranor, which is described as an oral small molecule therapy. Because the lead candidate is a small-molecule drug rather than a biologic, it fits the Pharmaceuticals category for branded prescription drug development.
COLL
Collegium Pharmaceutical
$760.32Mn
24.47
-0.97%
-43.79%
Collegium develops and markets branded prescription drugs, including Jornay PM for ADHD and Xtampza ER for pain management. Its revenue is generated from the sale of these branded pharmaceutical products to wholesale distributors.
ABUS
Arbutus Biopharma
$758.95Mn
3.82
+2.69%
-16.78%
Arbutus Biopharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically imdusiran, a GalNAc conjugated RNAi therapeutic. Its revenue model consists of licensing agreements, milestone payments, and royalties from biologic products like Alnylam's ONPATTRO.
ARDX
Ardelyx
$755.60Mn
3.01
+2.73%
-46.73%
Ardelyx is a biopharmaceutical company that researches, develops, and commercializes therapies derived from biological science, specifically its lead asset tenapanor. The company generates revenue from the sales of biologic-based products like IBSRELA and XPHOZAH, as well as milestone payments and royalties from collaboration partners such as Kyowa Kirin and Fosun Pharma.
ACHV
Achieve Life Sciences
$746.03Mn
6.78
+0.89%
+52.36%
Achieve Life Sciences is a specialty pharmaceutical company developing cytisinicline, a branded prescription drug for the treatment of nicotine dependence. The company's business model is centered on the development and future commercialization of this branded pharmaceutical product.
OABI
OmniAb
$743.86Mn
5.10
-3.77%
+242.28%
OmniAb's core business is a biotechnology platform that uses engineered transgenic animals and biological intelligence to discover and optimize antibodies and other target-binding proteins for human therapeutics. Its revenue is primarily derived from license agreements, milestones, and royalties from pharmaceutical and biotech partners developing biologic products.
JANX
Janux Therapeutics
$736.54Mn
12.04
-5.72%
-56.36%
Janux Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically T cell engagers and immunomodulators using its TRACTr, TRACIr, and ARM platforms. Its revenue is currently derived from collaboration and milestone payments from partners like Merck and Bristol Myers Squibb, which is characteristic of biotechnology developers.
OLMA
Olema Pharmaceuticals
$734.94Mn
7.27
-1.22%
-16.44%
Olema Pharmaceuticals is a clinical-stage company developing novel small molecule therapeutics, such as palazestrant and OP-3136, for breast cancer. Its business model focuses on the discovery, development, and eventual commercialization of branded prescription drugs.
SANA
Sana Biotechnology
$727.84Mn
2.43
-1.22%
-41.02%
Sana Biotechnology focuses on developing engineered cell therapies, specifically using a hypoimmune technology for stem cell derived islet cells (SC451) and a fusogen platform for in vivo CAR T cell generation (SG293). These activities involve modifying and replacing cells and delivering genetic material, which aligns directly with the Gene and Cell Therapy industry.
NVCT
Nuvectis Pharma
$724.92Mn
21.08
+0.76%
+247.28%
Nuvectis Pharma is a clinical-stage company developing small molecule drug candidates, specifically NXP900, which is a targeted small molecule inhibitor of SRC and YES1 kinases. Because its lead candidates are small-molecule drugs rather than biologics, it fits the Pharmaceuticals classification for branded prescription drug development.
CGEM
Cullinan Therapeutics
$722.60Mn
11.23
-4.02%
+50.94%
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically T cell engagers and bispecific antibodies like CLN-978 and CLN-049. Its revenue model is based on collaboration agreements, milestone payments, and royalties from partners such as Taiho Pharmaceutical.
FLGT
2nd
Fulgent Genetics
$715.73Mn
25.78
-1.41%
-5.08%
The company has a therapeutic development division focused on creating new drug formulations using nanoencapsulation technology, with candidates like FID 007 and FID 022 currently in phase one and two clinical trials.
CADL
Candel Therapeutics
$711.71Mn
9.35
-1.48%
+84.42%
Candel Therapeutics develops viral immunotherapies using engineered adenovirus and herpes simplex virus vectors to modify the tumor microenvironment. Its core platforms, including aglatimagene and linoserpaturev, are based on genetic modification of viruses to induce systemic anti-tumor immunity.
ZVRA
Zevra Therapeutics
$708.52Mn
11.92
-1.81%
+30.99%
Zevra Therapeutics develops and markets branded prescription drugs for rare diseases, specifically MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders. Its revenue is derived from the sale of these branded pharmaceutical products through specialty pharmacy distribution channels.
PRME
Prime Medicine
$704.88Mn
3.90
-9.30%
+10.48%
Prime Medicine focuses on developing genetic medicines using Prime Editing, a next-generation gene editing technology designed to modify genomic DNA. The company is developing in vivo programs for Wilson disease and alpha 1 antitrypsin deficiency, as well as an ex vivo program for chronic granulomatous disease.
NGNE
Neurogene
$700.15Mn
25.28
-2.77%
-10.67%
Neurogene is a clinical-stage company developing genetic medicines, specifically using an adeno-associated virus vector to deliver the MECP2 gene for the treatment of Rett syndrome. Its core EXACT technology focuses on regulating transgene expression, which is a hallmark of gene therapy development.
DCTH
2nd
Delcath Systems
$698.90Mn
20.10
-0.84%
+134.27%
The company markets the HEPZATO KIT, which is a drug/device combination involving the delivery of chemotherapy (melphalan) for the treatment of uveal melanoma liver metastases, and holds orphan drug designations for its therapies.
KURA
Kura Oncology
$695.52Mn
7.57
+0.00%
-26.65%
Kura Oncology discovers, develops, and markets branded prescription small-molecule therapeutics, specifically the FDA-approved drug KOMZIFTI for the treatment of NPM1-mutated AML. Its revenue is derived from the commercial sale of this branded pharmaceutical product.
AVBP
ArriVent BioPharma
$690.85Mn
13.49
-4.73%
-27.47%
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody-drug conjugates (ADCs) like ARR 217 and ARR 002. Its revenue model currently consists of collaboration and milestone payments, which is characteristic of biotechnology developers.
DSGN
Design Therapeutics
$679.31Mn
10.65
-1.39%
+43.34%
Design Therapeutics is a clinical-stage company developing GeneTAC molecules, which it explicitly describes as a 'novel class of small molecule' therapeutics. Because its core platform focuses on small-molecule drug discovery for branded prescription use (targeting diseases like Friedreich ataxia and Huntington's disease) rather than biologics, it fits the Pharmaceuticals category.
BCAX
Bicara Therapeutics
$675.47Mn
10.18
+2.00%
-26.92%
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional antibody therapies, specifically ficerafusp alfa, which is a biologic derived from biological science. Its core business is the research and development of these monoclonal antibody-based therapies for solid tumors.
WVE
Wave Life Sciences
$672.50Mn
3.41
-2.01%
-51.63%
Wave Life Sciences is a clinical-stage biotechnology company developing therapies derived from biological science, specifically RNA-based medicines including siRNA and antisense oligonucleotides. Its revenue is currently generated through collaboration agreements, milestone payments, and royalties from partners like GSK and Takeda.
ACRS
Aclaris Therapeutics
$625.92Mn
4.15
-2.12%
+94.84%
Aclaris Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies and bispecific antibodies like bosakitug and ATI-052. Its revenue model consists of upfront licensing fees, milestone payments, and royalties from collaborations with partners such as Biosion.
GERN
Geron
$624.91Mn
0.97
-3.00%
-16.38%
Geron is a biopharmaceutical company that developed RYTELO (imetelstat), a first-in-class telomerase inhibitor derived from biological science to treat myelodysplastic syndromes. The company generates revenue from the sale of this biologic product to healthcare providers and hospitals.
MNPR
Monopar Therapeutics
$613.18Mn
71.78
-2.82%
-13.60%
Monopar is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically MNPR 101, which is a humanized monoclonal antibody used for oncology imaging and therapy. The company's revenue model includes licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
IMMX
Immix Biopharma
$597.32Mn
8.35
-2.57%
+157.72%
Immix Biopharma is a clinical-stage company developing NXC 201, which is an autologous CAR T (chimeric antigen receptor T cell) therapy. Its core business is based on the N GENIUS platform for cell therapy and genetic modification to treat AL amyloidosis.
SGMT
Sagimet Biosciences
$578.42Mn
10.89
+0.55%
+30.73%
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing FASN inhibitors, such as denifanstat and TVB-3567, which are therapies derived from biological science. Its revenue model consists of licensing agreements and milestone payments from collaborators like Ascletis BioScience Co. Ltd.
OVID
Ovid Therapeutics
$568.46Mn
2.80
-1.75%
+107.41%
Ovid Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule medicines, such as the GABA aminotransferase inhibitor OV329, to treat brain disorders. Its business model targets the development of branded prescription pharmaceuticals for indications including epilepsy, psychosis, and neuropsychiatric manifestations.
PROK
Prokidney
$567.48Mn
1.11
-3.48%
-58.89%
ProKidney is developing rilparencel, an autologous cell therapy that involves expanding a patient's own renal cells outside the body and re-injecting them. This core platform of cellular modification and therapy fits the definition of Gene and Cell Therapy.
ENTX
Entera Bio
$563.51Mn
3.24
+0.31%
+8.00%
Entera Bio is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically oral tablet formulations of peptides and protein replacement therapies. Its pipeline includes candidates like EB613 (parathyroid hormone) and EB618 (GLP-1 glucagon agonist), and it generates funding through collaboration agreements and grants.
DMAC
DiaMedica Therapeutics
$521.46Mn
9.67
+0.21%
+59.57%
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing DM199 (rinvecalinase alfa), which is a recombinant human tissue kallikrein-1 (rhKLK1) protein. This is a biologic therapy derived from biological science, fitting the description of biotechnology-focused drug development.
CAPR
Capricor Therapeutics
$515.69Mn
8.87
-9.77%
+59.53%
Capricor Therapeutics focuses on the development of cell and exosome based therapeutics, specifically its lead candidate Deramiocel for Duchenne muscular dystrophy. The company's core platform is based on cellular modification and delivery, which aligns with the Gene and Cell Therapy classification.
VALN
Valneva SE
$509.34Mn
5.87
-0.84%
-33.97%
Valneva SE is a specialty vaccine company that develops and commercializes biologic therapies, specifically prophylactic vaccines like IXIARO, DUKORAL, and IXCHIQ. Its business model relies on the sale of these biologic products and the development of a clinical pipeline including candidates for Lyme disease and Zika virus.
RGNX
Regenxbio
$508.48Mn
7.69
-4.71%
-30.22%
REGENXBIO is a clinical-stage company focused on developing gene therapies using adeno-associated virus (AAV) vectors for retinal, neuromuscular, and neurodegenerative diseases. Its core business revolves around the NAV Technology Platform for genetic modification and the development of candidates like sura vec.
AKTX
Akari Therapeutics
$499.22Mn
7.13
-3.65%
-71.62%
Akari Therapeutics develops antibody-drug conjugates (ADCs), which are biologics consisting of antibodies linked to payloads. The company's revenue model is based on the future sale of these biologic products, as well as licensing, milestones, and royalties from biopharmaceutical partners.
GYRE
Gyre Therapeutics
$487.81Mn
4.23
-9.03%
-46.59%
Gyre Therapeutics is a commercial-stage company that develops and markets branded small-molecule prescription drugs. Its revenue is driven by the sale of branded therapies such as ETUARY® (pirfenidone), Etorel® (nintedanib), and Contiva® (avatrombopag).
AUTL
Autolus Therapeutics
$468.91Mn
1.32
+1.54%
+0.00%
Autolus Therapeutics develops and commercializes T cell therapies, specifically the CD19-directed chimeric antigen receptor T cell therapy AUCATZYL (obecabtagene autoleucel). Its core business is based on a T cell programming technology platform used to engineer cells for the treatment of cancer and autoimmune diseases.
KMDA
Kamada
$467.26Mn
8.10
+5.33%
+15.38%
Kamada is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically immunoglobulins extracted and purified from human plasma. Its proprietary products include KEDRAB, GLASSIA, and CYTOGAM, and it generates significant revenue from these biologic sales and royalties from Takeda.
SVA
Sinovac Biotech
$464.94Mn
6.47
+0.00%
—
Sinovac is a biopharmaceutical company that researches, develops, and commercializes vaccines, which are biological products. Its revenue is derived from the sale of biologic vaccines such as CoronaVac for COVID-19, Healive for hepatitis A, and Bilive for hepatitis A and B.
RLMD
Relmada Therapeutics
$455.48Mn
4.27
+2.64%
+41.86%
Relmada Therapeutics is a clinical-stage biotechnology company developing therapies such as sepranolone, a neurosteroid epimer, and NDV-01. The company's business model is based on biology-based drug discovery and development, with anticipated future revenue from product sales, milestones, and royalties.
ARVN
Arvinas
$453.26Mn
6.92
+2.37%
-38.16%
Arvinas is a clinical-stage biotechnology company that develops therapies using its proprietary PROTAC platform to degrade disease-causing proteins. Its revenue is derived from collaboration and licensing agreements with partners like Pfizer and Novartis, including upfront payments and milestones.
EOLS
Evolus
$450.43Mn
6.81
-2.16%
-3.40%
Evolus develops and markets branded prescription products for aesthetic use, specifically Jeuveau (a botulinum toxin) and Evolysse (hyaluronic acid gels). These are branded pharmaceutical products sold to licensed aesthetic practitioners for the treatment of frown lines and wrinkles.
PHAT
Phathom Pharmaceuticals
$442.66Mn
5.45
+2.25%
-60.31%
Phathom Pharmaceuticals develops and markets branded prescription drugs, specifically VOQUEZNA, VOQUEZNA DUAL PAK, and VOQUEZNA TRIPLE PAK for gastrointestinal diseases. Its revenue is generated solely from the sale of these branded pharmaceutical products in the United States.
AQST
Aquestive Therapeutics
$442.42Mn
3.52
-0.56%
-36.92%
Aquestive Therapeutics is a pharmaceutical company that develops and markets branded prescription drugs, such as Libervant for epilepsy rescue. Its business model focuses on creating alternative administration methods for complex molecules to replace standard of care therapies.
AGEN
Agenus
$439.79Mn
7.02
-1.82%
+66.75%
Agenus is a clinical-stage biotechnology company developing immune-modulatory antibodies and therapies derived from biological science to fight cancer and infections. Its revenue is derived from biologic-related royalty streams, upfront licensing payments, and milestones from partners like Bristol-Myers Squibb and Merck.
PRTA
Prothena Corp Public
$439.48Mn
8.56
-2.39%
-18.71%
Prothena is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically targeting protein dysregulation and misfolded proteins using its CYTOPE® platform. Its revenue is derived from collaboration and milestone payments from partners like Roche, Novo Nordisk, and Bristol Myers Squibb for biologic candidates targeting Parkinson's and Alzheimer's diseases.
TECX
Tectonic Therapeutic
$437.98Mn
21.97
+0.37%
+16.37%
Tectonic Therapeutic is a clinical-stage biotechnology company developing therapies derived from biological science, specifically therapeutic proteins and antibodies such as the TX45 Fc-relaxin fusion molecule and TX2100 VHH-Fc fusion antagonist antibody. Its core business is biology-based drug discovery using its proprietary GEODe platform to target G-protein coupled receptors.
BNTC
Benitec Biopharma
$432.06Mn
9.28
-5.98%
-28.01%
Benitec Biopharma is a clinical-stage company developing BB301, an adeno-associated virus (AAV) based gene therapy. Its core business is based on a 'silence and replace' platform designed to modify or replace genes to treat Oculopharyngeal Muscular Dystrophy.
CTMX
CytomX Therapeutics
$431.65Mn
1.98
+0.00%
-52.74%
CytomX is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically masked biologics including antibody-drug conjugates (ADCs), T-cell engagers, and cytokines. Its revenue is generated through collaboration and milestone payments from partners like Amgen and Bristol Myers Squibb, which is characteristic of the Biotechnology industry.
YDES
YD Bio
$426.86Mn
6.03
-11.06%
-30.45%
YD Bio is a biopharmaceutical company developing therapies derived from biological science, specifically mesenchymal stem cells and exosomes for ocular conditions like dry eye disease and glaucoma. Its revenue model includes the future sale of exosome-based eye drops and contact lenses.
ASMB
Assembly Biosciences
$423.80Mn
21.35
-1.93%
-33.43%
Assembly Biosciences is a biotechnology company that researches and develops antiviral therapies, such as the HDV entry inhibitor ABI-6250 and the HBV capsid assembly modulator ABI-4334. Its revenue is derived from collaboration and licensing agreements, including upfront and milestone payments from Gilead Sciences.
PBYI
Puma Biotechnology
$420.82Mn
8.14
-3.10%
+72.09%
Puma Biotechnology is a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically focusing on oncology. Its lead product, NERLYNX (neratinib), and its investigational drug alisertib are developed to treat HER2 positive breast cancer and small cell lung cancer.
CRMD
CorMedix
$417.07Mn
5.37
-1.83%
-51.53%
CorMedix develops and markets branded prescription pharmaceuticals, most notably DefenCath, an FDA-approved antimicrobial catheter lock solution. The company also sells a portfolio of branded anti-infective agents such as REZZAYO and VABOMERE, and the cardiovascular product TOPROL XL.
LYEL
Lyell Immunopharma
$411.74Mn
16.75
+8.63%
-5.26%
Lyell Immunopharma is a clinical-stage company developing autologous CAR T cell product candidates, which are engineered cell therapies. Its core platform focuses on genetic and cellular modification to treat hematologic malignancies and solid tumors.
XFOR
X4 Pharmaceuticals
$409.94Mn
3.24
-2.70%
-10.74%
X4 Pharmaceuticals develops and markets branded prescription drugs, specifically the small-molecule oral antagonist XOLREMDI (mavorixafor) for the treatment of WHIM syndrome. Its revenue is derived from the sale of this branded pharmaceutical product and associated licensing and royalty payments.
KARD
Kardigan
$408.57Mn
15.18
+0.00%
—
Kardigan is a clinical-stage company developing branded prescription medicines for cardiovascular diseases, such as Danicamtiv for genetic dilated cardiomyopathy and Ataciguat for calcific aortic valve stenosis. These are small-molecule oral therapeutics targeting specific disease root causes, fitting the profile of branded pharmaceutical development.
CTNM
Contineum Therapeutics
$405.40Mn
10.56
+2.52%
-2.67%
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing therapies derived from biological science, specifically modulating biological pathways like the lysophosphatidic acid 1 receptor. Its revenue is derived from collaboration agreements, licensing deals, and milestone payments, such as its agreement with Johnson & Johnson for the PIPE-307 asset.
IRD
Opus Genetics
$405.23Mn
4.23
+0.71%
+114.72%
Opus Genetics is primarily focused on developing gene therapies using adeno-associated virus (AAV) platforms to treat inherited retinal diseases, specifically targeting genes such as LCA5, BEST1, and RHO. Its core pipeline consists of seven AAV-based gene therapy programs, which align with the genetic modification focus of H-03.
CNTN
2nd
Canton Strategic Holdings
$403.37Mn
1.86
-3.63%
-49.32%
The company maintains a Biotechnology Research and Development segment through its subsidiary Gravitas, focusing on biologic therapeutic candidates like GV104 and GV023 for immunology and inflammation.
OCS
Oculis Holding AG
$396.53Mn
7.59
-2.32%
-60.92%
Oculis Holding AG is a biopharmaceutical company developing therapies derived from biological science, specifically Licaminlimab, which is a single chain antibody fragment. The company's core business is the research and development of these biologic-based drug candidates for ophthalmic diseases.
CCCC
C4 Therapeutics
$393.93Mn
3.00
-4.76%
+28.21%
C4 Therapeutics is a clinical-stage biopharmaceutical company that develops therapies derived from biological science, specifically targeted protein degradation using its TORPEDO platform. Its revenue is currently derived from collaboration and milestone payments from partners like Pfizer, Merck KGaA, and Roche, which is characteristic of biotechnology developers.
CYPH
2nd
Cypherpunk Technologies
$392.62Mn
2.13
-9.75%
+363.04%
Through its subsidiary Leap Therapeutics, the company develops antibody therapies for cancer, specifically leveraging a proprietary anti-DKK1 antibody platform for oncology treatments.
RZLT
Rezolute
$388.82Mn
4.02
+4.15%
-59.60%
Rezolute is a biotechnology company developing ersodetug, which is described as a human monoclonal antibody. The company's core business is the research and development of this biologic therapy for rare diseases like congenital and tumor-associated hyperinsulinism.
CBIO
Crescent Biopharma
$386.36Mn
13.92
+1.98%
+6.18%
Crescent Biopharma is a clinical-stage biotechnology company developing therapies derived from biological science, specifically bispecific antibodies and antibody drug conjugates. Its revenue is currently derived from upfront payments, milestone payments, and royalties from collaboration and licensing agreements with partners.
AVTX
Avalo Therapeutics
$386.09Mn
7.16
-1.51%
-52.96%
Avalo Therapeutics is a clinical-stage biotechnology company developing abdakibart (AVTX-009), which is described as a humanized IgG monoclonal antibody. Its business model focuses on the research and development of biologics to treat immune-mediated inflammatory diseases.
EDIT
Editas Medicine
$385.55Mn
2.51
-8.73%
-0.40%
Editas Medicine is a gene editing company that develops genomic medicines using CRISPR technology, specifically utilizing Cas9 and Cas12a to edit DNA in vivo and ex vivo. Its core business involves developing therapies for sickle cell disease, beta thalassemia, and hyperlipidemia through genetic modification.
SRZN
Surrozen
$384.30Mn
32.64
+2.00%
+176.61%
Surrozen is a biotechnology company developing antibody-based therapeutics, specifically multispecific antibodies using its proprietary SWAP platform. Its revenue is currently derived from collaboration agreements, licensing, and milestone payments from partners like Boehringer Ingelheim for these biologic candidates.
ALT
Altimmune
$377.28Mn
1.94
-8.49%
-54.46%
Altimmune is a biopharmaceutical company developing pemvidutide, a peptide engineered as a dual agonist of glucagon and GLP1 receptors. Its revenue model is typical of clinical-stage biotechnology firms, deriving from licensing arrangements and collaborative agreements while developing biologic-based therapies.
FENC
Fennec Pharmaceuticals
$370.66Mn
10.58
-2.31%
+37.76%
Fennec is described as a specialty pharmaceutical company focusing on a niche indication (cisplatin-induced ototoxicity). It generates revenue from the sale of its specialty therapy, PEDMARK, and through licensing and distribution agreements for the same product.
NIKA
Nika Pharmaceuticals
$369.14Mn
0.35
+0.00%
+16.67%
The company develops and distributes branded prescription medicinal products, specifically Thymus Nuclear Glycoprotein for HIV treatment and products based on the Inactivated Pepsin Fraction platform. These are sold to hospitals and healthcare providers for the treatment of patients.
SPRY
ARS Pharmaceuticals
$357.89Mn
3.57
+13.33%
-59.80%
ARS Pharmaceuticals develops and markets neffy, a branded prescription intranasal epinephrine spray for the emergency treatment of anaphylaxis. Revenue is generated from the sale of this branded pharmaceutical product to wholesalers and pharmacies.
ANL
Adlai Nortye
$342.00Mn
9.96
-10.67%
+530.38%
Adlai Nortye is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically antibody-drug conjugates (AN4035) and tri-specific antibody fusion proteins (AN8025). Its revenue is currently derived from collaboration and milestone payments from partners like Eisai and ASK Pharm, which is characteristic of biotechnology developers.
CAMP
Camp4 Therapeutics
$341.83Mn
4.33
-6.07%
+4.09%
Camp4 Therapeutics is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics, specifically antisense oligonucleotides, which are a form of oligonucleotide medicine. Its revenue is derived from collaboration and licensing agreements, such as the research collaboration with GlaxoSmithKline, which is characteristic of biotechnology developers.
IMUX
Immunic
$341.81Mn
8.04
+1.01%
+5.24%
Immunic is a biotechnology company researching and developing therapies derived from biological science, specifically targeting immunological targets for neurologic and gastrointestinal diseases. Its pipeline includes candidates like vidofludimus calcium (IMU 838) and IMU 856, which are currently in clinical stages.
MPLT
MapLight Therapeutics
$338.05Mn
7.44
+2.20%
-51.66%
MapLight Therapeutics is a biopharmaceutical company developing branded prescription drug candidates for CNS disorders, such as ML-007C-MA for schizophrenia and Alzheimer's disease psychosis. Its pipeline consists of small-molecule agonists and antagonists, such as the M1/M4 muscarinic agonist and the GPR52 positive allosteric modulator ML-009.
AVIR
Atea Pharmaceuticals
$337.28Mn
4.20
-4.76%
+26.13%
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically a proprietary platform of nucleosides and nucleotides. Its lead candidates, bemnifosbuvir and AT 587, are nucleotide analogs being developed to treat hepatitis C and hepatitis E.
NEUP
Neuphoria Therapeutics
$335.34Mn
2.69
-2.54%
-45.10%
Neuphoria is a clinical-stage biotechnology company developing therapies for neuropsychiatric disorders, specifically its lead candidate BNC210. Its revenue is derived from collaboration and milestone payments from partners like Merck, which is characteristic of the H-02 biotechnology classification.
CYDY
CytoDyn
$334.50Mn
0.23
-4.17%
-8.00%
CytoDyn is a clinical-stage biotechnology company developing leronlimab, which is specifically described as a humanized monoclonal antibody. Its revenue model is based on the typical biotech structure of milestone payments, royalties, and potential future sales of biologic products.
FTH
Faeth Therapeutics
$333.88Mn
12.92
+1.89%
+34.44%
Sensei Biotherapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, including antibody-based projects like solnerstotug and SNS 102. Its revenue model relies on external financing and potential collaboration/milestone payments typical of biotech developers.
EIKN
Eikon Therapeutics
$331.93Mn
6.13
+4.43%
—
Eikon Therapeutics is a clinical-stage biopharmaceutical company that researches and develops therapies for oncology, such as TLR 7/8 agonists and PARP1 inhibitors. Its revenue is derived from collaboration and licensing agreements, including upfront and milestone payments from partners like Impact Therapeutics Shanghai Inc.
ENTA
Enanta Pharmaceuticals
$326.73Mn
11.22
-2.18%
-2.52%
Enanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule therapeutics for virology and immunology, specifically targeting RSV, SARS-CoV-2, and hepatitis B. Its revenue model includes royalty payments from its collaboration with AbbVie for the hepatitis C regimen MAVYRET/MAVIRET, as well as potential milestone payments from its proprietary pipeline.
OCGN
Ocugen
$322.34Mn
0.95
-2.06%
-29.63%
Ocugen's core business is centered on its Modifier Gene Therapy Platform, which uses AAV5 vectors to deliver nuclear hormone receptor genes for treating inherited retinal diseases like retinitis pigmentosa and Stargardt disease. This focus on genetic modification for therapeutic purposes aligns directly with the Gene and Cell Therapy industry.
ALLO
Allogene Therapeutics
$322.04Mn
0.93
-12.26%
-21.19%
Allogene Therapeutics develops genetically engineered allogeneic T cell product candidates, specifically CAR T therapies, which involve modifying cells to treat cancer and autoimmune diseases. Its core platform relies on gene editing technologies from Cellectis (TALEN) and Arbor Biotechnologies (CRISPR) to create off-the-shelf cellular therapies.
PEPG
PepGen
$319.29Mn
4.61
+92.89%
+8.22%
PepGen is a clinical-stage biotechnology company developing oligonucleotide therapeutics, specifically using its EDO platform to create drugs like PGN EDODM1. Its business model focuses on the research and development of therapies derived from biological science to treat neuromuscular and neurologic diseases.
ELDN
Eledon Pharmaceuticals
$313.62Mn
2.76
-3.83%
+22.67%
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing tegoprubart, which is an engineered IgG1 antibody. Its business model focuses on biology-based drug discovery and development for indications such as kidney transplantation and ALS.
CABA
Cabaletta Bio
$312.79Mn
1.45
-3.33%
-40.33%
Cabaletta Bio focuses on developing engineered T cell therapies, specifically chimeric antigen receptor (CAR) T cells, to treat autoimmune diseases. Its lead product candidate, rese cel, is a CAR T construct designed to modify the immune system, which fits the definition of gene and cell therapy.
KYTX
Kyverna Therapeutics
$312.78Mn
5.08
-1.74%
-20.50%
Kyverna Therapeutics focuses on developing cell therapies, specifically its lead product candidate mivcel, which is an autologous CD19 directed chimeric antigen receptor (CAR) T cell therapy. The company's core platform is based on genetic and cellular modification to treat autoimmune diseases like stiff person syndrome and generalized myasthenia gravis.
EBS
Emergent BioSolutions
$309.85Mn
6.04
-0.98%
-45.04%
The company develops, manufactures, and markets branded prescription drugs and vaccines, including NARCAN Nasal Spray, anthrax vaccines, and smallpox vaccines. Its primary revenue is derived from the sale of these commercial and medical countermeasure products to government agencies and healthcare providers.
SWKHL
2nd
SWK Holdings
$304.94Mn
25.21
+0.12%
-1.18%
The company has a dedicated Pharmaceutical Development segment that engages in the development, manufacturing, and licensing of pharmaceutical compounds and drug delivery systems, such as its collaboration with Aptar.
EPRX
Eupraxia Pharmaceuticals
$304.87Mn
7.63
+2.83%
+22.47%
Eupraxia is a clinical-stage biotechnology company developing therapies derived from biological science, specifically utilizing its proprietary DiffuSphere™ microparticle system for drug delivery. Its lead candidates, EP-104GI and EP-104IAR, are currently in clinical trials (Phase 1b/2a and Phase 2b/3) for the treatment of eosinophilic esophagitis and osteoarthritis.
IPSC
Century Therapeutics
$303.32Mn
1.68
-6.67%
+205.45%
Century Therapeutics develops allogeneic pluripotent stem cell derived therapies and uses CRISPR-based gene editing and immune evasion technology to create off-the-shelf cell products. Its core platform is based on genetic and cellular modification for treating autoimmune diseases and cancer.
TTRX
Turn Therapeutics
$303.28Mn
9.92
+1.33%
+140.19%
Turn Therapeutics is primarily focused on developing GX-03, a non-biologic topical immunomodulator for moderate-to-severe eczema and onychomycosis. This activity constitutes the company's core drug development segment and targets the branded prescription pharmaceutical market.
PRLD
Prelude Therapeutics
$300.06Mn
3.76
+0.00%
+198.41%
Prelude Therapeutics is a biotechnology company focused on discovering and developing therapies derived from biological science, specifically protein degraders and antibody-drug conjugates (ADCs). Its revenue model is based on strategic partnerships, upfront payments, and milestone payments from collaborations with partners like Incyte and AbCellera.
OFIX
2nd
Orthofix Medical
$290.21Mn
7.12
-9.87%
-52.63%
The company sells biologics, including demineralized bone matrices, cellular allografts, and synthetic bone graft substitutes, which are therapies derived from biological science used to enhance bone fusion.
WHWK
Whitehawk Therapeutics
$289.11Mn
3.08
-4.05%
+41.28%
Whitehawk Therapeutics is a clinical-stage biotechnology company focused on developing antibody-drug conjugates (ADCs), which are biologic-based therapies. Its current pipeline includes candidates HWK-007, HWK-016, and HWK-206, which utilize a linker-payload platform to target tumor antigens.
EVMN
Evommune
$285.17Mn
7.86
+2.48%
-59.32%
Evommune is a clinical-stage biotechnology company developing therapies derived from biological science, specifically the fusion protein EVO301 which inhibits the IL 18 cytokine. Its revenue model consists of upfront payments, milestone payments, and royalties from partnerships with firms like Dermira, Maruho, and AprilBio.
ALEC
Alector
$284.06Mn
2.53
+2.85%
+93.13%
Alector is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like nivisnebart and latozinemab. Its revenue is generated through collaboration agreements, milestone payments, and royalties from pharmaceutical partners such as GSK.
NWBO
Northwest Biotherapeutics
$283.78Mn
0.17
+0.00%
-32.00%
Northwest Biotherapeutics develops personalized immune therapies using autologous dendritic cells, specifically DCvax®-L and DCvax®-Direct, which are engineered cell therapies for solid tumor cancers. This core platform of cellular modification and therapy fits the definition of Gene and Cell Therapy.
FULC
Fulcrum Therapeutics
$283.78Mn
3.72
+0.00%
-51.50%
Fulcrum Therapeutics is a clinical-stage company developing branded prescription small molecules, specifically its lead candidate pociredir for the treatment of sickle cell disease. The company's core business is the discovery and development of small-molecule drugs to treat genetically defined rare diseases.
IKT
Inhibikase Therapeutics
$281.11Mn
1.55
-7.19%
-2.52%
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing IKT-001, an oral prodrug of imatinib, which is a small-molecule branded prescription drug candidate for pulmonary arterial hypertension.
KRRO
Korro Bio
$281.05Mn
15.73
+5.15%
-51.78%
Korro Bio is a biopharmaceutical company developing therapies derived from biological science, specifically using RNA editing and oligonucleotides. Its pipeline includes KRRO 121 and programs for alpha 1 antitrypsin deficiency and ALS, which are characteristic of biotechnology-focused drug development.
SABS
SAB Biotherapeutics
$279.79Mn
3.07
-0.97%
-4.06%
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically multi-specific high potency human immunoglobulin G. Its lead candidate, SAB 142, is a biologic designed to treat autoimmune type 1 diabetes.
LRMR
Larimar Therapeutics
$279.45Mn
2.69
+6.32%
-24.23%
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, which is described as a recombinant fusion protein. Its core business is based on a cell penetrating peptide (CPP) technology platform to create therapies derived from biological science.
QTTB
Q32 Bio
$278.89Mn
9.33
-0.11%
+283.95%
Q32 Bio is a clinical-stage biotechnology company developing biologics, specifically monoclonal antibodies like bempikibart (ADX-914) and a tissue-targeted complement inhibitor platform. Its revenue is derived from collaboration and licensing agreements with partners such as Bristol-Myers Squibb and Akebia Therapeutics, which include upfront payments and milestones.
RCKT
Rocket Pharmaceuticals
$268.37Mn
2.45
-3.16%
-22.22%
Rocket Pharmaceuticals focuses on developing genetic therapies using AAV and lentiviral vectors to treat rare diseases. Its product candidates, such as RP-A501 for Danon disease and KRESLADI (RP-L201) for Leukocyte Adhesion Deficiency-I, are designed to modify or replace genes to correct underlying genetic causes.
ARCT
Arcturus Therapeutics Holdings
$267.25Mn
9.39
-1.05%
+6.95%
Arcturus is a biotechnology company focused on developing therapies and vaccines derived from biological science, specifically using a proprietary self-amplifying mRNA platform. Its revenue is generated from biologic product sales of its COVID-19 vaccine KOSTAIVE, as well as collaboration and milestone payments from partners like CSL Seqirus.
BIOA
BioAge Labs
$265.60Mn
5.78
+1.76%
-22.83%
BioAge Labs is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases using a proprietary platform based on multi-omic data. Its revenue is derived from collaboration agreements and milestones with pharmaceutical partners like Lilly and Novartis, which is characteristic of biotechnology developers.
LCTX
Lineage Cell Therapeutics
$265.55Mn
1.05
-2.78%
-41.99%
Lineage Cell Therapeutics specializes in cell replacement therapies, specifically developing allogeneic cell therapies like OpRegen and OPC1 that replace damaged or destroyed cells. Its core business is based on a cell therapy platform using pluripotent stem cells to create mature, differentiated cells for transplantation.
DTIL
Precision Biosciences
$264.98Mn
9.50
-1.86%
+56.51%
Precision Biosciences is a clinical-stage gene editing company that develops in vivo therapeutic candidates using its proprietary ARCUS nuclease platform to create permanent genetic treatments. Its focus on DNA editing for disorders like Duchenne muscular dystrophy and hepatitis B aligns directly with the gene and cell therapy classification.
VTVT
vTv Therapeutics
$260.90Mn
21.00
-0.85%
-24.97%
vTv Therapeutics focuses on developing orally administered small-molecule therapies, such as the liver selective glucokinase activator cadisegliatin and a PDE4 inhibitor. These are branded prescription drug candidates targeting metabolic and inflammatory diseases like type 1 and type 2 diabetes.
BCYC
Bicycle Therapeutics
$258.27Mn
3.69
-2.12%
-43.92%
Bicycle Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically synthetic short peptides (Bicycle molecules). Its revenue is currently derived from collaboration and licensing arrangements with partners like Ionis and Bayer, as well as milestone payments.
IMMP
Immutep
$252.65Mn
3.46
-8.95%
+98.85%
Immutep is a biotechnology company focused on developing LAG3-related immunotherapies, including monoclonal antibodies and the lead candidate eftilagimod alfa. Its revenue model is based on licensing agreements, milestone payments, and royalties from partners like Novartis and EOC Pharma.
IMRX
Immuneering
$249.34Mn
3.85
+5.48%
-44.28%
Immuneering is a clinical oncology company developing branded prescription anti-cancer medicines, specifically its lead product candidate atebimetinib, an oral MEK inhibitor. The company's core business is the discovery and development of a novel class of medicines called Deep Cyclic Inhibitors.
ELTP
Elite Pharmaceuticals
$247.74Mn
0.23
-4.17%
-63.49%
Elite Pharmaceuticals is a specialty pharmaceutical company focused on the development and manufacture of generic versions of controlled-release drug products. Its revenue is primarily derived from the sale of generic equivalents such as Phentermine, Amphetamine, and Methadone under its ANDA segment.
AMRN
Amarin Corp Plc\Uk
$247.71Mn
11.75
+0.00%
-25.87%
Amarin is a pharmaceutical company that develops and markets branded prescription drugs, specifically its flagship product VASCEPA (icosapent ethyl). Its revenue is primarily generated from the sale of this branded pharmaceutical to wholesalers and through licensing agreements with commercial collaborators.
VNDA
Vanda Pharmaceuticals
$246.71Mn
4.08
-0.24%
-7.69%
Vanda Pharmaceuticals develops and markets branded prescription drugs such as Fanapt for schizophrenia and PONVORY for multiple sclerosis. Its revenue is generated primarily from the sale of these branded pharmaceutical products to wholesalers and specialty pharmacies.
INCY
Incyte
$245.42Mn
120.30
-1.26%
+13.51%
Incyte is a biopharmaceutical company that discovers, develops, and markets branded prescription drugs such as JAKAFI, ICLUSIG, and OPZELURA. Its revenue is primarily derived from the sale of these branded pharmaceutical products to specialty pharmacies, hospital pharmacies, and wholesalers.
LXEO
Lexeo Therapeutics
$240.59Mn
3.06
-2.55%
-64.08%
Lexeo Therapeutics is a clinical-stage genetic medicine company developing gene therapy candidates for cardiovascular diseases and Alzheimer's. Its core platform utilizes the AAVrh10 vector to modify or replace genes to treat conditions like Friedreich ataxia and PKP2 mutations.
PALI
Palisade Bio
$239.59Mn
1.13
-4.24%
-36.16%
Palisade Bio is a clinical-stage biopharmaceutical company developing PALI-2108, a small-molecule oral phosphodiesterase-4 (PDE4) inhibitor prodrug. Its business model focuses on the discovery and development of branded prescription pharmaceuticals for inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease.
AGMB
AgomAb Therapeutics
$238.83Mn
6.99
-7.42%
—
AgomAb Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, including the HGF-mimetic monoclonal antibody AGMB-101. Its business model focuses on biology-based drug discovery and development for fibro-inflammatory diseases.
IRLA
IRulya Therapeutics
$236.85Mn
38.62
+14.33%
-87.93%
Quince Therapeutics is a biotechnology company that developed the AIDE technology platform to encapsulate therapeutic agents within red blood cells. Its lead candidate, eDSP, was a biologic-based delivery system for dexamethasone phosphate targeting ataxia telangiectasia.
GLSI
Greenwich LifeSciences
$235.88Mn
16.07
-2.72%
+86.43%
Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing immunotherapy products, specifically GLSI-100, which utilizes the GP2 peptide and GM-CSF. These are biological components designed to elicit an immune response, fitting the description of therapies derived from biological science.
OMER
Omeros
$234.42Mn
17.30
-1.42%
+162.12%
Omeros is a biotechnology company that develops therapies derived from biological science, specifically protein therapeutics and antibodies such as YARTEMLEA (narsoplimab-wuug) and OMS1029. Its revenue is generated from the sale of these biologic products and collaboration payments from partners like Novo Nordisk.
ETRA
Electra Therapeutics
$234.34Mn
7.99
-2.80%
—
Electra Therapeutics is a biopharmaceutical company developing monoclonal antibodies, specifically ipsoprubart and ELA822, which are biologics derived from biological science. Its revenue model is based on the development and potential commercialization of these biologic product candidates for immune-mediated diseases and cancer.
ACIU
AC Immune
$232.99Mn
2.29
-6.15%
-31.64%
AC Immune is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically active immunotherapies targeting proteinopathies. Its revenue is generated through collaboration and milestone payments from pharmaceutical partners for these biologic candidates.
PLX
Protalix BioTherapeutics
$230.43Mn
2.86
+11.72%
+34.27%
Protalix is a biopharmaceutical company that develops and commercializes therapies derived from biological science, specifically recombinant therapeutic proteins produced via its ProCellEx plant cell-based expression system. Its revenue is derived from the sale of biologic products like Elelyso and Elfabrio, as well as milestone payments and royalties.
SIGA
Siga Technologies
$224.91Mn
3.13
-3.99%
-51.92%
SIGA Technologies is a commercial-stage pharmaceutical company that develops and markets TPOXX (tecovirimat), a branded prescription antiviral drug. Its revenue is derived from the sale of this branded pharmaceutical to the U.S. government (BARDA and Department of Defense) and foreign health agencies.
GALT
Galectin Therapeutics
$224.13Mn
3.38
-1.74%
-35.00%
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically proprietary complex carbohydrates from plant-based materials. It focuses on the discovery and development of agents to inhibit galectin 3 for the treatment of fibrotic diseases and cancer.
FATE
Fate Therapeutics
$215.18Mn
1.77
-8.76%
+62.39%
Fate Therapeutics focuses on creating off-the-shelf cellular immunotherapies using an induced pluripotent stem cell (iPSC) platform to generate engineered T cell and NK cell product candidates. Its core business is the development of therapies that modify and replace cells, specifically targeting autoimmune diseases and solid tumors through CAR T and CAR NK cell candidates.
RNAC
Cartesian Therapeutics
$210.06Mn
6.89
-1.85%
-4.83%
Cartesian Therapeutics develops cell therapy treatments using a proprietary mRNA-based technology to modify patients' own T cells ex vivo. The company's core platform focuses on engineered cell therapies (CAR-T) for autoimmune diseases like myasthenia gravis and lupus.
TRDA
Entrada Therapeutics
$205.54Mn
5.25
+11.94%
-27.69%
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically nucleic acid therapeutics using its Endosomal Escape Vehicle (EEV) platform. Its revenue is currently derived from collaboration and milestone payments, such as those from Vertex Pharmaceuticals for the development of VX-670.
ARTV
Artiva Biotherapeutics
$200.70Mn
4.06
-3.79%
+10.93%
Artiva Biotherapeutics is a clinical-stage company developing cell-based therapies, specifically allogeneic off-the-shelf natural killer (NK) cell therapies like AlloNK and CAR-NK programs (AB-201 and AB-205). Its core platform is based on cellular modification and the use of cord blood starting material to treat autoimmune diseases and cancers.
CGEN
Compugen
$197.62Mn
2.09
-2.34%
+25.15%
Compugen is a clinical-stage biotechnology company that develops antibody-based therapies, such as COM701 and COM902, derived from biological science. Its revenue model is based on biologic product collaborations, milestone payments, and royalties from partners like Gilead and AstraZeneca.
ADCT
ADC Therapeutics
$192.88Mn
1.51
-9.04%
-64.13%
ADC Therapeutics develops and commercializes antibody drug conjugates (ADCs), which are biologics, specifically ZYNLONTA for B-cell lymphomas. Its revenue is derived from biologic product sales and licensing collaborations involving milestone payments and royalties.
ACOG
Alpha Cognition
$190.09Mn
8.73
-1.91%
+39.46%
Alpha Cognition develops, manufactures, and markets ZUNVEYL, a branded prescription oral tablet for the treatment of mild to moderate Alzheimer's disease. Revenue is generated from the commercial sale of this branded pharmaceutical product through wholesalers and pharmacies.
INDP
Indaptus Therapeutics
$185.93Mn
2.90
-7.35%
+15.54%
Indaptus Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically using attenuated non-pathogenic Gram-negative bacteria for immunotherapy. Its lead candidate, Decoy20, is being evaluated in clinical trials for advanced solid tumors.
UPB
Upstream Bio
$185.26Mn
3.38
-5.59%
-85.62%
Upstream Bio is a clinical-stage biotechnology company developing verekitug, which is a monoclonal antibody. Its business model focuses on the research and development of biologic therapies for inflammatory respiratory diseases like severe asthma and COPD.
KROS
Keros Therapeutics
$185.02Mn
9.33
+1.74%
-45.25%
Keros Therapeutics is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically engineered ligand traps and protein therapeutics. Its revenue is currently derived from collaboration and milestone payments from partners like Takeda and Hansoh for candidates such as elritercept.
MDWD
MediWound
$181.10Mn
14.11
+0.21%
-21.52%
MediWound develops and commercializes biologics, specifically enzymatic therapeutics like NexoBrid, for wound and burn care. Its revenue model includes biologic product sales, royalties, and milestone payments, which aligns with the Biotechnology classification.
ANIK
2nd
Anika Therapeutics
$180.43Mn
13.47
-7.55%
+33.76%
The company has a Nonorthopedic Products segment that includes Hyvisc, a high molecular weight injectable hyaluronic acid specifically for equine joint dysfunction, sold to veterinary clinics.
ZURA
Zura Bio
$178.80Mn
1.40
+12.90%
-64.19%
Zura Bio is a clinical-stage biotechnology company developing antibody-based therapies, such as tibulizumab and torudokimab, derived from biological science. Its revenue model relies on equity offerings, debt, and potential milestone payments from partnerships with larger pharmaceutical firms.
ZNTL
Zentalis Pharmaceuticals
$176.87Mn
1.80
+3.45%
+36.36%
Zentalis is a clinical-stage company developing azenosertib, which is described as an oral small molecule inhibitor of the WEE1 kinase. Because it is developing a branded small-molecule pharmaceutical for oncology rather than a biologic, it fits the Pharmaceuticals category.
BBOT
BridgeBio Oncology Therapeutics
$176.55Mn
2.20
-4.35%
-82.66%
BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically targeting the RAS and PI3Kα oncogenes. Its pipeline includes investigational agents such as BBO-8520, BBO-11818, and BBO-10203, which are currently in phase 1 clinical trials.
DRUG
Bright Minds Biosciences
$172.65Mn
22.61
-6.22%
-61.87%
Bright Minds Biosciences is a biotechnology company developing therapies derived from biological science, specifically targeting serotonin receptor subtypes for neurological and psychiatric disorders. Its lead candidate BMB 101 and other pipeline compounds (BMB 105, BMB 201, BMB 202) are developed using a proprietary platform of biased agonists and structure-based drug design.
SLGL
Sol-Gel Technologies
$171.35Mn
61.50
+0.15%
+89.64%
Sol-Gel develops and markets branded prescription topical treatments for dermatology, specifically Twyneo for acne vulgaris and Epsolay for rosacea. The company generates revenue from these branded products through licensing agreements, royalties, and milestone payments from partners like Mayne Pharma.
STRO
Sutro Biopharma
$168.58Mn
10.17
-4.15%
+25.56%
Sutro Biopharma is a clinical-stage oncology company developing antibody-drug conjugates (ADCs), which are biologic therapies. Its revenue is derived from collaboration and license agreements, milestone payments, and royalties from partners like Astellas Pharma and Merck Sharp & Dohme.
IVVD
Invivyd
$168.01Mn
0.57
-5.00%
-64.60%
Invivyd is a biopharmaceutical company that researches and commercializes monoclonal antibody therapies, such as PEMGARDA, which are derived from biological science. Its revenue is generated from the sale of these biologic products and milestone payments from collaborations with Adimab.
XLO
Xilio Therapeutics
$167.94Mn
8.53
-5.22%
-24.31%
Xilio Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically masked bispecific antibodies, T cell engagers, and cytokine-based therapies. Its revenue is currently derived from collaboration and milestone payments from pharmaceutical partners like AbbVie and Gilead.
SION
Sionna Therapeutics
$167.27Mn
3.70
+3.64%
-89.66%
Sionna Therapeutics is a clinical-stage company developing small molecule therapies, such as SION-719 and SION-451, to treat cystic fibrosis. These drug candidates are designed as branded prescription pharmaceuticals targeting the CFTR protein's nucleotide binding domain 1.
ANTX
AN2 Therapeutics
$164.30Mn
4.33
+8.25%
+266.95%
AN2 Therapeutics is a clinical-stage biopharmaceutical company that researches and develops therapies derived from its proprietary boron chemistry platform. Its revenue model consists of licensing agreements, milestone payments, and royalties from partners like Anacor Pharmaceuticals and Brii Biosciences, which is characteristic of the Biotechnology industry.
ORMP
Oramed Pharmaceuticals
$164.02Mn
3.97
-0.75%
+74.12%
Oramed is a biotechnology company focused on the research and development of an oral insulin capsule and a technology platform for the oral delivery of therapeutic proteins. Its core business is the development of biology-based therapies to compete with other insulin developers and pharmaceutical firms.
HUMA
Humacyte
$163.90Mn
0.59
+28.26%
-56.30%
Humacyte develops and commercializes bioengineered human tissues, specifically acellular tissue engineered vessels like Symvess, which fall under the category of cell and gene therapy/regenerative medicine. The company's core platform focuses on creating universally implantable tissues that remodel with host cells, a hallmark of cellular modification and regenerative therapy.
EQ
Equillium
$163.24Mn
1.46
-2.67%
+50.52%
Equillium is a biotechnology innovator developing therapies derived from biological science, specifically targeting interleukin 15 and interleukin 21. The company is currently a clinical-stage developer with preclinical candidates EQ504 and EQ302.
MGNX
Macrogenics
$154.02Mn
2.42
+3.42%
+69.23%
MacroGenics is a biopharmaceutical company that develops antibody-based therapeutics using proprietary biological platforms like DART and TRIDENT. Its revenue is derived from the sale of biologic products, royalties, and milestone payments from collaborations with partners like Gilead.
ALXO
Alx Oncology Holdings
$153.42Mn
1.11
-11.90%
-12.60%
Alx Oncology Holdings is a clinical-stage biotechnology company developing therapies derived from biological science, specifically the CD47 blocking fusion protein evorpacept and the EGFR targeted antibody-drug conjugate ALX2004. Its current revenue is generated through collaboration and licensing agreements with partners like Jazz Pharmaceuticals and Sanofi, which is characteristic of the H-02 classification.
CMPX
Compass Therapeutics
$151.27Mn
0.84
+0.00%
-80.37%
Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics, specifically using its proprietary StitchMabs platform to create bispecific antibodies. Its revenue is derived from collaboration and milestone payments from partners like ABL Bio and Adimab, which is characteristic of the Biotechnology industry.
AKBA
Akebia Therapeutics
$149.86Mn
0.54
+1.89%
-67.66%
Akebia Therapeutics develops and commercializes branded prescription drugs for kidney disease, specifically Vafseo for anemia and Auryxia for phosphorus control. Its revenue is primarily generated from the sale of these branded pharmaceuticals in the United States.
TARA
Protara Therapeutics
$149.62Mn
2.43
-3.19%
-46.36%
Protara Therapeutics is a clinical-stage company whose core platform, TARA-002, is described as an investigational cell therapy used for treating non-muscle invasive bladder cancer and lymphatic malformations. This aligns with the H-03 classification for companies developing therapies that modify or replace cells.
INO
Inovio Pharmaceuticals
$143.02Mn
1.45
-3.97%
-32.56%
Inovio is a clinical-stage biotechnology company developing DNA medicines for HPV-associated diseases, cancer, and infectious diseases. Its revenue is derived from biologic-focused activities including license fees, milestone payments, and collaborative R&D agreements with partners like ApolloBio and AstraZeneca.
IPHA
Innate Pharma
$142.45Mn
1.52
+0.66%
-33.91%
Innate Pharma is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically therapeutic antibodies and the ANKET platform for engaging natural killer cells. Its revenue model consists of upfront payments, milestone payments, and royalties from collaborations with biopharma partners like AstraZeneca and Sanofi.
RNA
Atrium Therapeutics
$140.78Mn
8.23
-1.79%
—
Atrium Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically siRNA-based therapies (oligonucleotides) and monoclonal antibodies. Its revenue is currently derived from collaboration and milestone payments, such as the $15.0 million recognized under the BMS Collaboration Agreement.
ABEO
Abeona Therapeutics
$140.06Mn
2.45
-3.54%
-42.08%
Abeona Therapeutics develops and commercializes cell and gene therapies, specifically its lead approved product ZEVASKYN, an autologous cell-based gene therapy. The company also maintains a pipeline of adeno-associated virus (AAV) based gene therapies using its proprietary AIM™ capsid platform.
PRQR
ProQR Therapeutics
$138.02Mn
1.31
-5.07%
-39.35%
ProQR Therapeutics is a clinical-stage biotechnology company that develops RNA editing therapeutics using its proprietary Axiomer platform. Its revenue is derived from collaboration agreements, such as the $125 million upfront payment from Eli Lilly, and research grants for biologic-based drug discovery.
ARMP
Armata Pharmaceuticals
$137.07Mn
3.69
-3.66%
-40.58%
Armata Pharmaceuticals is a clinical-stage biotechnology company developing therapies derived from biological science, specifically bacteriophage therapeutics. Its lead candidates, such as AP-PA02 and AP-SA02, are biologics designed to target antibiotic-resistant bacterial infections.
OKUR
OnKure Therapeutics
$136.90Mn
3.38
+5.30%
+10.10%
OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines, specifically small molecule inhibitors like OKI-219. The company's core activity is biology-based drug discovery and development targeting mutant proteins in cancers.
PYXS
Pyxis Oncology
$136.12Mn
1.63
-4.12%
-65.83%
Pyxis Oncology is a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs), which are biologic therapies. Its revenue is derived from collaboration and licensing agreements with partners like Merck, Pfizer, and Biosion, as well as milestone payments.
MENS
Jyong Biotech
$136.09Mn
1.79
-3.24%
-95.38%
Jyong Biotech is a biopharmaceutical company that discovers, develops, and manufactures branded prescription drugs such as Botreso® for benign prostatic hyperplasia and PCP for prostate cancer prevention. Its revenue model is based on the commercialization of these proprietary drug candidates and licensing agreements.
SPRB
Spruce Biosciences
$134.13Mn
46.67
-4.91%
-59.63%
Spruce Biosciences is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically TA-ERT (an enzyme replacement therapy) and SPR202 (an anti-CRH monoclonal antibody). Its revenue model is based on licensing agreements, milestone payments, and royalties from partnerships with other biotech and pharma firms.
LENZ
LENZ Therapeutics
$128.82Mn
4.10
-4.43%
-82.32%
LENZ Therapeutics is a commercial pharmaceutical company that develops and markets VIZZ (aceclidine ophthalmic solution), a branded prescription drug for treating presbyopia. Its revenue is derived from the sale of this branded pharmaceutical product and associated international licensing and royalty agreements.
NTHI
Neonc Technologies Holdings
$126.08Mn
4.37
+16.84%
-56.90%
NeOnc is a biopharmaceutical company developing branded prescription drug candidates, specifically NEO100 and NEO212, for the treatment of intracranial malignancies and Parkinson's disease. Its business model focuses on the discovery and clinical development of these small-molecule compounds derived from perillyl alcohol.
MOLN
Molecular Partners Ag
$125.16Mn
3.10
-1.27%
-27.06%
Molecular Partners AG is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically using its proprietary DARPin platform to create recombinant proteins. Its revenue is generated through collaboration and milestone payments from partners like Orano Med and Eckert & Ziegler for the development of biologic product candidates.
ATRA
Atara Biotherapeutics
$124.14Mn
8.10
+0.50%
-34.15%
Atara Biotherapeutics develops and commercializes allogeneic T cell therapies, specifically its lead product Ebvallo tab cel, which modifies and utilizes cells to treat cancer and autoimmune diseases. The company's core platform is based on cellular modification and the use of allogeneic T cells, fitting the definition of Gene and Cell Therapy.
NERV
Minerva Neurosciences
$124.09Mn
2.49
-5.32%
-34.65%
Minerva Neurosciences is a clinical-stage biopharmaceutical company developing roluperidone, a branded prescription drug candidate for the treatment of schizophrenia. The company's business model focuses on the discovery and development of proprietary small-molecule product candidates for central nervous system diseases.
ORGO
2nd
Organogenesis Holdings
$122.01Mn
0.94
+3.30%
-85.63%
The company develops and commercializes therapies derived from biological science, specifically bioengineered skin substitutes like Apligraf and Dermagraft, as well as placental allografts and porcine collagen matrices.
ZSQR
Z Squared
$121.90Mn
2.30
-17.27%
-84.16%
The company focuses on acquiring and developing cell therapy technologies, specifically utilizing the SNAP-CAR platform and GEAR technology to engineer natural killer (NK) cells for treating cancer and autoimmune diseases. These activities involve modifying cells to create therapies for hematologic malignancies and solid tumors, which aligns directly with the Gene and Cell Therapy classification.
DERM
Journey Medical
$121.52Mn
4.42
-2.21%
-50.61%
Journey Medical is a commercial-stage pharmaceutical company that sells and markets FDA-approved branded prescription drugs for dermatological conditions, such as Emrosi, Qbrexza, and Accutane. Its revenue is primarily generated from the sale of these branded pharmaceutical products.
IBIO
iBio
$118.23Mn
0.78
+0.00%
-39.53%
iBio is a preclinical stage biotechnology company developing precision antibody therapeutics, which are biologics. Its revenue is derived from collaboration and licensing agreements, milestone payments, and royalties, specifically through its alliance with AstralBio.
PYPD
PolyPid
$114.87Mn
6.31
+1.45%
+68.72%
PolyPid is a biopharmaceutical company developing therapies derived from biological science and specialized delivery platforms, such as its long-acting GLP-1 receptor agonist and OncoPLEX for oncology. Its revenue currently comes from collaboration payments, milestones, and licensing agreements, which is characteristic of biotechnology developers.
FHTX
Foghorn Therapeutics
$113.93Mn
1.90
-6.86%
-57.01%
Foghorn Therapeutics is a clinical-stage biotechnology company that develops therapies derived from biological science, specifically targeting the chromatin regulatory system. Its revenue is generated through strategic collaborations, such as the partnership with Eli Lilly, which includes upfront payments, milestones, and royalties.
VYGR
Voyager Therapeutics
$113.78Mn
1.83
-8.04%
-57.04%
Voyager Therapeutics focuses on developing gene therapies and genetic medicines, specifically utilizing adeno-associated virus (AAV) capsids to deliver therapeutic payloads to the brain. Its core business revolves around the TRACER platform for genetic modification and delivery to treat neurological diseases like Alzheimer's and Parkinson's.
ENGN
enGene Therapeutics
$111.91Mn
1.67
-5.65%
-72.21%
enGene is a clinical-stage company developing non-viral genetic therapies, specifically using its DDX platform to deliver genetic cargos (DNA and RNA) to treat bladder cancer. Its lead candidate, detalimogene voraplasmid, is a genetic medicine designed to modify the immune response in mucosal tissues.
RANI
Rani Therapeutics Holdings
$111.44Mn
0.56
-1.75%
-69.89%
Rani Therapeutics is a clinical-stage biotherapeutics company developing oral delivery for biologics such as GLP-1/GLP-2 dual agonists, adalimumab, and ustekinumab. Its revenue is currently derived from collaboration and license agreements, including upfront payments and milestones from partners like Chugai Pharmaceutical and Celltrion.
CLLS
Cellectis
$111.38Mn
1.11
-0.89%
-68.73%
Cellectis is a clinical-stage company focused on gene editing to create allogeneic CAR T cell products using its proprietary TALEN nuclease platform. Its core business involves modifying T cells to create universal therapies for immuno-oncology, which fits the definition of gene and cell therapy.
MSLE
Satellos Bioscience
$109.60Mn
7.09
-5.34%
+17.19%
Satellos Bioscience is a clinical-stage biotechnology company that uses its proprietary MyoReGenX platform to develop therapies for severe muscle conditions. Its lead program targets Duchenne muscular dystrophy by inhibiting the protein kinase AAK1 to promote muscle regeneration.
NGEN
Nervgen Pharma
$105.93Mn
1.33
-4.32%
-44.58%
NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG 291, which is described as a humanized peptide. Peptides are specifically listed as a biology-based therapy under the Biotechnology industry classification.
ANIX
Anixa Biosciences
$105.83Mn
3.06
-3.16%
-26.97%
Anixa Biosciences focuses on developing chimeric endocrine receptor-T cell therapy (CAR-T) for ovarian cancer and other solid tumors. This core platform involves engineering T cells to target specific receptors, which falls directly under the modification and replacement of cells described in the Gene and Cell Therapy industry.
AVXL
Anavex Life Sciences
$104.75Mn
1.13
-7.38%
-82.59%
Anavex is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting the sigma 1 receptor for CNS diseases. Its lead candidates, ANAVEX 2 73 and ANAVEX 3 71, are being developed for Alzheimer's, Parkinson's, and Rett syndrome, and the company currently generates revenue through research grants and collaborations.
VANI
Vivani Medical
$102.82Mn
1.15
+2.68%
-23.84%
Vivani Medical is a clinical-stage biopharmaceutical company developing branded drug implant candidates, specifically focusing on GLP1 receptor agonists for obesity and type 2 diabetes. Its primary business model is the development and potential commercialization of these branded prescription therapies.
CRDL
Cardiol Therapeutics
$102.26Mn
1.02
-1.92%
-2.86%
Cardiol Therapeutics is a clinical-stage company developing small molecule drug candidates, specifically CardiolRx and CRD 38, for the treatment of inflammatory heart diseases like pericarditis and myocarditis. These are branded prescription pharmaceutical candidates targeting specific therapeutic areas.
UNCY
Unicycive Therapeutics
$101.95Mn
3.66
-1.08%
-22.29%
Unicycive Therapeutics is a clinical-stage biotechnology company developing therapies for kidney disease, specifically oxylanthanum carbonate for hyperphosphatemia and UNI 494 for acute kidney injury. Its revenue model is based on the future sale of these biologic/drug products and current licensing agreements providing milestone payments and royalties.
NRXP
NRX Pharmaceuticals
$101.85Mn
2.36
-0.84%
-7.09%
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics for CNS disorders, such as NRX 100 and NRX 101, which focus on modulating the NMDA receptor. Its core business is the research and development of these biology-based drug candidates.
NBP
NovaBridge Biosciences
$99.23Mn
0.86
-4.44%
-79.95%
NovaBridge Biosciences is a biotechnology platform company focused on the discovery and development of therapies derived from biological science, specifically bispecific antibodies. Its pipeline includes candidates like gavastomig and uliledlimab, and it generates revenue through licensing agreements, collaboration arrangements, and milestone payments.
CHRS
Coherus Oncology
$98.90Mn
0.64
-21.95%
-49.21%
Coherus Oncology develops and commercializes therapies derived from biological science, specifically the anti-PD-1 antibody LOQTORZI. Its revenue is generated from the sale of this biologic product and through licensing fees, milestone payments, and royalties from collaboration agreements.
CUE
Cue Biopharma
$98.10Mn
18.76
-7.40%
-8.17%
Cue Biopharma is a clinical-stage company developing biologics, specifically bifunctional fusion proteins and engineered biologics using its ImmunoSTAT platform. Its revenue is derived from collaboration and license agreements with partners like Boehringer Ingelheim and LG Chem, which is characteristic of biotechnology drug developers.
ADAG
Adagene
$97.14Mn
2.05
-3.30%
+29.75%
Adagene is a clinical-stage biotechnology company developing antibody-based cancer immunotherapies, such as its lead candidate ADG126 (a masked anti-CTLA-4 antibody). Its revenue is derived from collaboration and milestone payments from partners like Sanofi and Exelixis, which is characteristic of the H-02 classification.
NKTX
Nkarta
$96.80Mn
1.35
-15.09%
-31.12%
Nkarta is a clinical-stage company developing allogeneic engineered natural killer (NK) cell therapies, specifically its lead candidate NKX019. Its core business is based on a proprietary NK cell engineering platform that modifies cells to express chimeric antigen receptors, which fits the definition of cell therapy.
HURA
TuHURA Biosciences
$96.16Mn
1.51
-8.48%
-39.11%
TuHURA Biosciences is a clinical-stage biotechnology company developing therapies derived from biological science, including the TBS-2025 VISTA-inhibiting antibody and a DOR-targeted antibody-drug conjugate platform. Its revenue model is typical of biotech, consisting of licensing fees, milestone payments, and collaborative research funding from partners like Merck.
CATX
Perspective Therapeutics
$95.40Mn
0.79
-8.14%
-64.41%
Perspective Therapeutics is a biotechnology company developing therapies derived from biological science, specifically linking the isotope Lead 212 to tumor-specific targeting peptides for cancer treatment. Its revenue model consists of upfront fees, milestone payments, and royalties from collaborations with partners like Lantheus and Bristol Myers Squibb.
LONA
LeonaBio
$95.38Mn
4.02
-10.07%
-12.23%
LeonaBio is a biopharmaceutical company developing small molecule candidates, specifically lasofoxifene for metastatic breast cancer and ATH 1105 for ALS. These are branded prescription drug candidates rather than biologics, fitting the description of Pharmaceuticals.
PLYX
Polaryx Therapeutics
$93.21Mn
1.87
-2.60%
—
Polaryx Therapeutics is a clinical-stage biotechnology company developing therapies for rare pediatric lysosomal storage diseases. Its revenue model consists of licensing agreements, milestone payments, and royalties, which is characteristic of the H-02 classification.
ICCC
Immucell
$93.18Mn
10.26
+0.39%
+68.75%
ImmuCell is an animal health biologics company that develops and manufactures products specifically for neonatal dairy and beef calves. Its primary revenue comes from the sale of First Defense®, a product used to prevent calf scours in livestock.
NMRA
Neumora Therapeutics
$88.31Mn
0.47
-4.08%
-83.27%
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric and neurodegenerative disorders, such as navacaprant for major depressive disorder and NMRA-511 for Alzheimer's agitation. Its revenue model consists of milestone payments and royalties from collaborations with partners like Amgen and The Scripps Research Institute, which is characteristic of biotechnology developers.
ZOMDF
Zomedica
$88.20Mn
0.09
+0.00%
-10.00%
Zomedica is an animal health company that develops and markets diagnostic and therapeutic products specifically for companion animals, including dogs, cats, and horses. Its revenue is derived from selling veterinary-specific products like the TRUFORMA diagnostic platform and PulseVet shockwave therapy devices to veterinarians.
VXRT
Vaxart
$87.73Mn
0.36
-5.26%
-10.00%
Vaxart is a clinical-stage biotechnology company that develops recombinant vaccines using a proprietary adenovirus type 5 vector platform. Its core business involves researching and developing biology-based therapies for norovirus, SARS-CoV-2, influenza, and HPV.
ELOX
Eloxx Pharmaceuticals
$87.58Mn
12.90
-4.52%
—
Eloxx Pharmaceuticals is a clinical-stage company developing small molecule therapeutics, such as exaluren, to treat rare kidney diseases. Its revenue model is based on branded pharmaceutical development, including licensing agreements with partners like Almirall, S A for the development of ZKN 013.
IFRX
InflaRx
$87.47Mn
1.21
-6.92%
-23.42%
InflaRx is a biopharmaceutical company whose primary commercial product, vilobelimab (GOHIBIC), is a monoclonal antibody used to treat SARS CoV 2 induced ARDS. The company also develops other biology-based therapies like IFX002, which is another anti-C5a antibody.
RVRC
Revium Rx
$86.84Mn
1.43
+0.00%
+175.00%
Revium Rx is a pre-clinical stage biopharmaceutical company developing therapies derived from biological science, specifically nanoparticle-based and lipid-based delivery systems. Its product pipeline includes nano-formulations for antibiotics, oncology, and a Liposomal Protein-Loaded Technology (LPLT) platform for vaccines.
TNYA
Tenaya Therapeutics
$84.33Mn
0.37
-5.13%
-74.13%
Tenaya Therapeutics is a clinical-stage company whose core platform focuses on gene therapy candidates, specifically TN-201 and TN-401, which target genetically defined subpopulations with disease-modifying approaches. Its business model relies on platform collaborations, such as the research agreement with Alnylam Pharmaceuticals, and grants for clinical trials of these gene therapies.
RLYB
Rallybio
$84.05Mn
15.76
+0.64%
+203.08%
Rallybio is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies like RLYB116 (a C5 inhibitor) and RLYB332 (a matriptase 2 inhibitor). Its current revenue is derived from collaboration agreements, licensing deals, and milestone payments from partners such as Sanofi and Johnson & Johnson.
MIST
Milestone Pharmaceuticals
$82.17Mn
0.66
-10.81%
-64.32%
Milestone Pharmaceuticals is a biopharmaceutical company that researches and develops therapies derived from biological science, specifically focusing on etripamil for cardiovascular conditions. Its revenue is generated from the sale of its lead biologic-based product, CARDAMYST, and potential milestone payments and royalties from collaboration partners.
CRBP
Corbus Pharmaceuticals Holdings
$80.98Mn
3.93
+11.33%
-62.43%
Corbus is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically an antibody drug conjugate targeting Nectin 4. Its revenue model currently consists of licensing agreements, such as the one with CSPC for CRB 701, which is characteristic of biotechnology developers.
PMVP
PMV Pharmaceuticals
$80.80Mn
1.22
-1.61%
-6.15%
PMV Pharmaceuticals focuses on the discovery and development of small molecule therapies, such as its lead candidate rezatapopt, to treat p53-related cancers. The company's revenue model is based on the future sales of these branded prescription pharmaceuticals and potential licensing agreements.
CPIX
Cumberland Pharmaceuticals
$79.41Mn
5.30
-1.30%
+167.68%
Cumberland Pharmaceuticals focuses on the acquisition, development, and commercialization of branded prescription pharmaceuticals. It generates revenue from the sale of FDA-approved branded products such as Acetadote, Caldolor, and Vibativ.
TLPH
Talphera
$79.30Mn
1.05
-3.67%
-17.32%
Talphera is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics, specifically small molecule drug candidates like TP-0184. Its revenue model relies on collaborations, licensing agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
TNXP
Tonix Pharmaceuticals Holding
$78.52Mn
4.10
-9.09%
-75.65%
Tonix Pharmaceuticals is a fully-integrated company that discovers, develops, and markets branded prescription drugs. It generates revenue from the sale of FDA-approved branded products such as TONMYA for fibromyalgia and Zembrace SymTouch and Tosymra for acute migraine.
TENX
Tenax Therapeutics
$76.96Mn
1.69
-5.06%
-75.82%
Tenax Therapeutics is a development-stage pharmaceutical company focused on branded prescription therapies for pulmonary hypertension. Its lead product candidates, levosimendan (TNX-103) and imatinib, are small-molecule drugs being developed for commercial sale to healthcare providers and patients.
APMD
Apnimed
$76.16Mn
15.86
+0.32%
—
Apnimed is a pharmaceutical company developing Oxnimbi, a branded prescription oral therapy consisting of a fixed-dose combination of aroxybutynin and atomoxetine. The company's revenue model is based on the future sales of this branded prescription drug for the treatment of obstructive sleep apnea (OSA).
RTGN
2nd
RetinalGenix Technologies
$75.19Mn
3.99
+0.00%
+24.69%
The company is developing pharmaceutical therapies, specifically RTG-2023 for dry AMD and RTG-2024 for Alzheimer's syndrome dementia, which fall under the research and development of therapies for systemic and ophthalmic diseases.
COYA
Coya Therapeutics
$74.13Mn
3.16
-5.11%
-46.89%
Coya Therapeutics is a clinical-stage biotechnology company developing therapies derived from biological science, specifically biologics that enhance regulatory T cells (Tregs). Its pipeline includes COYA 302, a combination biologic utilizing a proprietary low-dose IL2 backbone.
TLSA
Tiziana Life Sciences
$73.51Mn
0.61
-8.96%
-65.14%
Tiziana Life Sciences is a clinical-stage biotechnology company developing therapies derived from biological science, specifically monoclonal antibodies such as Foralumab (anti-CD3) and TZLS 501 (anti-IL 6 receptor). Its business model focuses on biology-based drug discovery and development for neurodegenerative and neuroinflammatory diseases.
ZYBT
Zhengye Biotechnology Holding
$72.98Mn
1.54
+3.36%
-25.60%
Zhengye Biotechnology Holding focuses on the research, development, manufacturing, and sale of veterinary vaccines for livestock, including swine, cattle, goats, sheep, poultry, and dogs. Its revenue is generated primarily from the sale of these animal-health products under its own brand.
HRTX
Heron Therapeutics
$70.40Mn
0.37
+0.00%
-66.67%
Heron Therapeutics is described as a biotechnology company that leverages advanced science and proprietary Biochronomer technology to develop therapies. Its revenue is derived from the sale of biologic-style innovative products like ZYNRELEF and CINVANTI, which are differentiated through unique formulations and delivery mechanisms.
NTRB
NutriBand
$70.02Mn
5.76
-3.36%
-3.52%
Nutriband focuses on developing abuse-deterrent versions of existing generic drugs, such as AVERSA Fentanyl, AVERSA Buprenorphine, and AVERSA Methylphenidate. These products utilize the 505(b)(2) regulatory pathway to create specialty pharmaceuticals based on approved generic ingredients.
GOSS
Gossamer Bio
$68.99Mn
11.28
+5.92%
-94.31%
Gossamer Bio is a biopharmaceutical company developing seralutinib, an inhaled small molecule inhibitor, for the treatment of pulmonary arterial hypertension. Its revenue model is based on collaboration agreements, such as the one with Chiesi, and potential future sales of these branded prescription drugs.
MNOV
Medicinova
$68.91Mn
1.40
-4.76%
-0.71%
Medicinova is developing oral small molecule therapeutics, specifically MN 166 and MN 001, for indications such as multiple sclerosis and glioblastoma. These are branded prescription drug candidates rather than biologics, fitting the description of pharmaceutical discovery and development.
ACRV
Acrivon Therapeutics
$67.27Mn
1.57
-0.63%
-22.66%
Acrivon is a clinical-stage biopharmaceutical company that researches and develops therapies derived from biological science, specifically focusing on precision medicines for cancer. Its revenue model includes licensing agreements, milestone payments, and royalties, as seen in its agreement with Eli Lilly for ACR-368.
CSBR
2nd
Champions Oncology
$66.11Mn
4.75
-3.46%
-29.94%
The company pursues internal drug discovery and development programs focused on targeted therapy, immune oncology, and cell therapy to create novel oncology therapeutics for partnership or outlicensing.
MAIA
MAIA Biotechnology
$65.45Mn
1.06
-1.85%
-7.83%
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing ateganosine, a targeted immunotherapy for cancer. Its revenue model currently relies on collaboration and milestone payments from partners like Regeneron and BeOne Medicines, which is characteristic of biotechnology developers.
SMNR
Semnur Pharmaceuticals
$65.31Mn
0.30
+3.45%
-96.67%
Semnur Pharmaceuticals is developing SP-102, a branded prescription injectable formulation of dexamethasone sodium phosphate for the treatment of sciatica. The company's business model is centered on the discovery, development, and potential commercialization of this branded pharmaceutical product.
IMA
ImageneBio
$65.24Mn
3.81
-2.06%
-53.54%
ImageneBio is a clinical-stage biopharmaceutical company developing IMG-007, which is a monoclonal antibody. Monoclonal antibodies are specifically listed as therapies derived from biological science under the Biotechnology industry.
ASBP
Aspire-Lakewood Holdings
$63.98Mn
8.52
+0.12%
+38.31%
Aspire is an early-stage biopharmaceutical company developing a sublingual delivery platform for drug candidates, including a high-dose aspirin formulation for myocardial infarction prevention. Its business model includes potential revenue from the sale of these approved drug candidates and future licensing or collaboration agreements.
CGTX
Cognition Therapeutics
$63.72Mn
0.67
-2.90%
-60.12%
Cognition Therapeutics is a clinical-stage company developing zervimesine (CT1812), which is explicitly described as an orally delivered small molecule therapeutic. The company's core business is the discovery and development of branded prescription small-molecule drugs for Alzheimer's disease and dementia with Lewy bodies.
FBIO
Fortress Biotech
$63.62Mn
1.91
-4.02%
-26.25%
Fortress Biotech operates as a biopharmaceutical company that researches and commercializes therapies derived from biological science, specifically through its subsidiary Mustang Bio, which develops CAR T-cell therapies for oncology and rare diseases. The company's revenue model includes biologic product sales, milestone payments, and royalties from its diversified portfolio of biotech assets.
CING
Cingulate
$63.36Mn
4.56
+2.47%
+25.62%
Cingulate is a biopharmaceutical company developing branded prescription drugs for ADHD and anxiety, such as CTx-1301 (dexmethylphenidate) and CTx-2103 (buspirone). Its revenue model is based on the development and commercialization of these branded pharmaceutical products.
IAM
Iambic Therapeutics
$63.00Mn
14.78
+11.46%
—
Iambic Therapeutics develops and owns a pipeline of branded prescription small-molecule inhibitors, such as IAM1363 for HER2-altered solid tumors and IAM217 for KIF18A, which are in clinical and preclinical development.
OTLK
Outlook Therapeutics
$62.90Mn
0.46
+0.00%
-63.49%
Outlook Therapeutics develops and commercializes ONS 5010 LYTENAVA, which is an ophthalmic formulation of bevacizumab, a monoclonal antibody (biologic). The company's revenue is derived from the sale of this biologic product to hospitals and clinics for the treatment of retinal diseases.
CLNN
Clene
$62.68Mn
4.41
+0.68%
-56.29%
Clene is a clinical-stage pharmaceutical company developing branded prescription therapeutics such as CNM-Au8 for the treatment of neurodegenerative diseases like ALS, MS, and Parkinson's. Its core business model is the discovery, development, and potential commercialization of these novel nanotechnology-based drugs.
CNXU
2nd
Conexeu Sciences
$60.82Mn
2.22
-4.72%
—
The company operates a Veterinary Care segment that adapts its collagen scaffold for animal trauma and surgical healing in dogs, cats, and horses, targeting veterinary hospitals.
VRCA
Verrica Pharmaceuticals
$60.47Mn
3.52
-2.49%
-9.04%
Verrica Pharmaceuticals develops and markets branded prescription drugs for dermatologic diseases, specifically its lead product YCANTH for molluscum contagiosum. Revenue is generated from the sales of this branded pharmaceutical product to healthcare providers.
CTOR
Citius Oncology
$60.42Mn
0.56
+0.00%
-60.84%
Citius Oncology is a biopharmaceutical company that developed LYMPHIR, an engineered IL 2 diphtheria toxin fusion protein, which is a biologic therapy. Revenue is generated from the sale of this biologic product and through collaboration milestone payments and royalties.
XBIT
XBiotech
$60.06Mn
1.97
+3.14%
-19.59%
XBiotech researches and develops monoclonal antibodies, which are biologics, for treating oncology, rheumatology, and infectious diseases. Its revenue model includes biologic product sales, licensing agreements, and milestone payments, such as the $750 million sale of Bermekimab.
SPRO
Spero Therapeutics
$58.73Mn
1.01
-5.61%
-59.60%
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases, such as tebipenem HBr. Its revenue model consists of license agreements, milestone payments, and royalties from partners like GlaxoSmithKline, which is characteristic of biotechnology developers.
NMAD
Nomad Power Solutions
$58.28Mn
3.78
+5.29%
-12.50%
Lixte is a clinical-stage biopharmaceutical company developing cancer therapies, specifically inhibitors of protein phosphatase 2A such as LB 100. Its business model focuses on biology-based drug discovery and development with expected revenue from licensing, partnerships, and future product sales.
CVM
Cel Sci
$58.11Mn
1.40
+2.19%
-80.53%
CEL-SCI is a biotechnology company developing therapies derived from biological science, specifically Multikine, which is described as a biological medicinal immunotherapy comprised of natural cytokines and small biological molecules. The company is currently in the clinical-stage of development for these biologic product candidates.
PDSB
PDS Biotechnology
$57.60Mn
1.03
-4.63%
+5.10%
PDS Biotechnology is a clinical-stage company developing immunotherapies and vaccines derived from biological science, specifically using its Versamune and Infectimune platforms. Its pipeline includes biologic candidates like PDS0101 for HPV-related cancers and PDS0202 for influenza.
RNXT
2nd
RenovoRx
$56.86Mn
1.18
+0.00%
+18.00%
The company is developing a drug-device combination candidate, intra arterial gemcitabine delivered via RenovoCath (IAG), which is currently in a Phase III trial for locally advanced pancreatic cancer.
APTN
Adaptin Bio
$56.76Mn
6.27
+0.00%
—
Adaptin Bio focuses on integrating gene therapy and cell therapy to treat brain cancers, specifically through its lead candidate APTN-101 which redirects T cells against tumors. The company's core platform is based on cellular modification and the delivery of therapeutics to the CNS.
BOLD
Boundless Bio
$56.02Mn
2.45
-0.41%
+102.48%
Boundless Bio is a clinical-stage oncology company developing small molecule drugs to inhibit targets in ecDNA biology. Its pipeline consists of ecDNA directed therapeutic candidates intended for patients with oncogene amplified cancers such as breast and gastric cancer.
NORD
Nordicus Partners
$55.60Mn
2.90
-17.61%
-40.21%
Nordicus Partners is a biotech company that researches and develops therapies derived from biological science, specifically monoclonal antibody (MaB) therapy for psoriasis via its NoviThera ApS segment. The company's business model focuses on acquiring and advancing preclinical biotechnology firms to develop drug candidates like QR-01, QR-02, and QR-04.
RFL
Rafael Holdings
$55.50Mn
1.08
+0.93%
-16.92%
Rafael Holdings is primarily a biotechnology company developing therapies derived from biological science, such as Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 and the liposomal prodrug Promitil® via LipoMedix.
CRDF
Cardiff Oncology
$54.12Mn
0.79
+0.00%
-64.57%
Cardiff Oncology is a clinical-stage biotechnology company focused on the research and development of onvansertib, a highly selective PLK1 inhibitor. Its revenue model is based on clinical development milestones and potential future licensing agreements for this biologic-based drug candidate.
TRXB
TRex Bio
$53.20Mn
13.13
-3.38%
—
TRex Bio is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically monoclonal antibodies (TRB-071) and Fc-fusion proteins (TRB-061). Its revenue model is based on collaboration and milestone payments, such as the $55 million upfront payment and $15 million milestone from Eli Lilly.
INKT
MiNK Therapeutics
$51.02Mn
10.01
-1.38%
-27.31%
MiNK Therapeutics develops allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, such as agenT-797, MiNK-215, and MiNK-413. These products are engineered cell therapies designed to modify the immune response to treat cancer and immune-mediated diseases, which fits the core platform of genetic or cellular modification.
CELZ
Creative Medical Technology Holdings
$50.38Mn
0.60
+0.00%
-81.71%
The company develops regenerative therapies using stem cells and immune cells, specifically through platforms like ImmCelz™, AlloStem™, and StemSpine®. Its core business is the modification and application of cellular therapies to treat conditions such as type 1 diabetes and disc degeneration.
ARTL
Artelo Biosciences
$49.32Mn
2.16
+2.86%
-96.21%
Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically targeting lipid signaling and the endocannabinoid system. Its product candidates, such as ART27.13 and ART26.12, are being developed for conditions like cancer-related anorexia and chemotherapy-induced peripheral neuropathy.
ATNM
Actinium Pharmaceuticals
$49.05Mn
1.56
-0.64%
+17.29%
Actinium is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically radioconjugates and antibody-based therapeutics like Actimab-A and ATNM-400. Its revenue model is based on the development of these biologic product candidates, strategic partnerships, and potential milestones.
PLRX
Pliant Therapeutics
$48.92Mn
0.79
-1.25%
-51.23%
Pliant Therapeutics is developing small molecule inhibitors, such as its lead candidate PLN-101095, which is described as an oral, small molecule dual inhibitor. Since the company focuses on branded small-molecule drug discovery and development for oncology indications, it fits the Pharmaceuticals classification.
VERU
Veru
$48.87Mn
2.12
-3.20%
-18.46%
Veru is a biopharmaceutical company developing branded prescription drugs, specifically enobosarm for obesity and sabizabulin for atherosclerotic cardiovascular disease. These are small-molecule oral medicines (a selective androgen receptor modulator and a microtubule disruptor) intended for branded pharmaceutical sales.
MREO
Mereo BioPharma
$47.91Mn
0.30
+0.00%
-83.05%
Mereo BioPharma is a biopharmaceutical company developing therapies for rare diseases, including setrusumab and alvelestat. Its revenue model currently consists of upfront payments, milestone payments, and royalties from collaborations with partners like Ultragenyx and Feng Biosciences, which is characteristic of biotechnology developers.
GANX
Gain Therapeutics
$47.87Mn
1.08
-0.92%
-56.63%
Gain Therapeutics is a biotechnology company that researches and develops therapies derived from biological science, specifically using its Magellan platform to design allosteric regulators (STARs). Its lead candidate, GT 02287, and other preclinical programs for Gaucher disease and Alzheimer's are typical of biology-based drug discovery and development.
ONCY
Oncolytics Biotech
$47.36Mn
0.38
-5.00%
-64.49%
Oncolytics Biotech is a clinical-stage biopharmaceutical company developing pelareorep, an oncolytic virus derived from a reovirus strain, which is a therapy derived from biological science. The company's revenue model is based on the future sale of this biologic product, as well as potential licensing fees and milestone payments from collaborators.
HOWL
Werewolf Therapeutics
$47.14Mn
0.97
-3.96%
-16.38%
Werewolf Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically conditionally activated cytokines (IL-2, IL-12, IL-21, etc.) and T-cell engagers. Its revenue is currently derived from collaboration and licensing agreements, such as the one with Jazz Pharmaceuticals for JZP898, which is typical for clinical-stage biotechnology developers.
ELTX
Elicio Therapeutics
$45.57Mn
1.61
-1.83%
-81.75%
Elicio Therapeutics is a clinical-stage biotechnology company developing immunotherapies derived from biological science, specifically using its Amphiphile AMP technology to generate T cell responses. Its lead candidate, ELI-002 7P, and other programs targeting BRAF and TP53 are biology-based drug discovery efforts.
SGMOQ
Sangamo Therapeutics
$45.57Mn
0.11
+0.00%
-78.43%
Sangamo Therapeutics is a genomic medicine company that develops therapies modifying or replacing genes, specifically using zinc finger protein technology for epigenetic regulation and AAV capsids for delivery. Its pipeline includes gene therapy candidates for Fabry disease (ISARALGAGENE CIVAPARVOVEC) and hemophilia A (GIROCTOCogene FITELPARVOVEC).
KLRS
Kalaris Therapeutics
$44.52Mn
1.87
-23.05%
-61.04%
Kalaris Therapeutics is a clinical-stage biopharmaceutical company developing TH103, which is described as a fully humanized recombinant fusion protein. This falls under the biotechnology category as it is a therapy derived from biological science (recombinant proteins) aimed at treating retinal diseases.
CRBU
Caribou Biosciences
$44.30Mn
0.41
-2.38%
-80.19%
Caribou Biosciences focuses on developing allogeneic CAR-T cell therapies, such as vispa-cel and CB-011, which are engineered cell therapies. The company's core platform is its proprietary chRDNA genome-editing technology used for precise genomic edits, including TCR knockout and HLA-E insertion.
SCTX
Scribe Therapeutics
$43.14Mn
17.36
+4.08%
—
Scribe Therapeutics is a clinical-stage company developing therapies based on CRISPR technologies, specifically gene editing (XE technology) and epigenetic silencing (ELXR technology). Its product pipeline includes STX-1200 and STX-1400, which are designed to edit and inactivate the LPA and APOC3 genes, respectively.
TIL
Instil Bio
$43.07Mn
6.35
-1.85%
-57.12%
Instil Bio is a clinical-stage biopharmaceutical company developing bispecific antibodies, specifically AXN-2510/IMM2510, which is a biologic therapy derived from biological science targeting PD-L1 and VEGF for oncology.
CNTB
Connect Biopharma Holdings
$42.82Mn
0.68
-9.33%
-55.26%
Connect Biopharma is a clinical-stage biopharmaceutical company developing rademikibart, which is specifically described as a monoclonal antibody. Its revenue model currently consists of license and collaboration agreements, milestone payments, and royalties, which is characteristic of biotechnology developers.
UG
United Guardian
$42.08Mn
9.16
+3.50%
+45.40%
The company's largest revenue stream (51%) comes from pharmaceutical products, specifically Renacidin, which is an FDA-approved drug for preventing and dissolving urethral catheter calcifications.
ATHE
Alterity Therapeutics
$42.05Mn
2.32
-4.53%
-38.13%
Alterity Therapeutics is a biotechnology company focused on the discovery and development of therapeutic candidates for neurodegenerative disorders, such as its lead candidate ATH434. Its revenue model includes licensing agreements, research collaborations, and grant funding, which is characteristic of clinical-stage biotech developers.
DWTX
Dogwood Therapeutics
$41.98Mn
1.23
+2.50%
-77.88%
Dogwood Therapeutics is a biopharmaceutical company developing therapies derived from biological science, specifically synthetic peptides like the SP16 program and tetrodotoxin derivatives for the Halneuron program. The company is in the development stage with no product revenue, relying on grants and licensing agreements to fund its clinical-stage pipeline.
ELUT
2nd
Elutia
$41.29Mn
0.93
+10.71%
+8.14%
The company develops therapies derived from biological science, specifically human acellular dermal matrices (SimpliDerm) and porcine small intestinal submucosa extracellular matrices, which are biologic scaffolds used in reconstructive surgery.
